Intermediate filaments as tissue specific markers in urological cancers by Feitz, W.F.J.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/113396
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
INTERMEDIATE FILAMENTS AS TISSUE SPECIFIC MARKERS 
Ш UROLOGICAL CANCERS 
^ш 
H 
Н Н 
^Ш 
J^'--
ММ • 
бйЖ Ш/М 4jr 
•••ле
1 
, , J 
Î r f^ 
^л 
'J* 
ш ш 
:-,· ,^ 
_:·•:••'••: • 
•••пк 

INTERMEDIATE FILAMENTS AS TISSUE SPECIFIC MARKERS 
IN UROLOGICAL CANCERS 
Page 2 
INTERMEDIATE FILAMENTS AS TISSUE SPECIFIC MARKERS 
IN UROLOGICAL CANCERS 
PROEFSCHRIFT 
TER VERKRIJGING VAN DE GRAAD VAN DOCTOR 
Ш DE GENEESKUNDE 
AAN DE KATHOLIEKE UNIVERSITEIT TE NIJMEGEN, 
OP GEZAG VAN DE RECTOR MAGNIFICUS 
PROF. DR. J.H.G.I. GŒSBERS 
VOLGENS BESLUIT VAN HET COLLEGE VAN DEKANEN 
IN HET OPENBAAR TE VERDEDIGEN 
OP DONDERDAG 29 MEI 1986 
DES NAMIDDAGS TE 4.00 UUR 
DOOR 
WOUTER FRANCISCUS JOANNUS FEITZ 
GEBOREN TE LICHTENVOORDE 
Druk Oissertatiedrukkenj Wibro, Helmond 
Page 4 
Promotores: Prof. Dr. F.M.J. Debruyne 
Prof. Dr. G.P. Vooijs 
Co-referenten: Prof. Dr. C.J. Herman 
Dr. F.C.S. Ramaekers 
No part of this book may be reproduced by any mechanical, 
photographic, or electronic process, or in the form of a 
phonographic recording, nor may it be stored in a retrieval 
system, transmitted, or otherwise copied for public or 
private use, without the written permission of the author. 
CIP-DATA KONINKLIJKE BIBLIOTHEEK, DEN HAAG 
Feitz, Wouter Franciscus Joannus 
Intermediate filaments as tissue specific markers in 
urological cancers / Wouter Franciscus Joannus Feitz ; 
[ill. by the author]. - [S.l : s.n.]. - 111. 
Thesis Nijmegen. - With ref. - With summary in Dutch. 
ISBN 90-9001209-5 
SISO 605.91 UDC 616.6-006.6:611.6 
Subject headings: intermediate filaments / urology / 
cancer. 
We like to thank for support of this publication: 
Becton and Dickinson, Euro-Diagnostics B.V., Labsystems, 
Ortho Diagnostic Systems and Sanbio B.V. 
This study was part of the long-term research program 
"Pathobiology and epidemiology of (pre-) malignant lesions". 
Page 5 
Voor Marie-Jose' 
Page 6 
Page 7 
CONTENTS PAGE 
CHAPTER I: Introduction 
CHAPTER II: Intermediate filament proteins as tissue 
specific markers in normal and malignant 
urological tissues 
9 
19 
CHAPTER III: Antibodies to cytokeratin and vimentin 
in testicular tumor diagnosis 
45 
CHAPTER IV: Application of antibodies to intermediate 
filament proteins as tissue specific probes 
in the flow cytometric analysis of complex 
tumors 
67 
CHAPTER V: Tissue specific markers in flow cytometry of 
urological cancers: cytokeratins in bladder 
carcinoma 
Θ5 
CHAPTER VI: Tissue specific markers in flow cytometry of 
urological cancers: cytokeratin and vimentin 
in renal cell tumors 
103 
CHAPTER VII: Summary and conclusions, 
samenvatting en conclusies 
119 
Dankwoord 133 
Curriculum vitae 135 
Page В 
Page 9 
CHAPTER I 
INTRODUCTION 
Page 10 
Page 11 
INTRODUCTION 
In the diagnostic procedures of a disease, the 
histopathological diagnosis is an essential step in the 
classification and management of a patients' disease. 
Standardization of such procedures of tumor diagnosis in 
oncology has led to the establishment of staging and grading 
criteria for most tumors. The staging procedures for 
urological tumors such as kidney, bladder, prostate and 
testis tumors have been described by the UICC and are based 
on the extent of disease at the moment of diagnosis (22). 
The histological criteria for typing of urological tumors 
has been extensively described for kidney tumors by 
Bennington and Beckwith (5), for bladder tumors by Koss and 
Mostofi et al. (31, 51) and for the male genital system by 
Mostofi et al. (38, 52). Although quite uniform in 
histological appearence different patients in the same state 
of the disease, show different responses to treatment as a 
result of still unpredictable factors influencing the course 
of the disease, despite uniform treatment protocols. The 
clinical behaviour of a certain tumor is hard to predict for 
each individual patient (12). 
For example, the prognosis of the disease in kidney 
tumors is characterised by the macroscopic extent of the 
primary tumor, and shows no correlation with the 
histopathological appearence of the neoplasm (41, 44, 48). 
Depth of invasion of bladder tumors defines the patients 
survival rate after treatment, but recurrence and 
progression of this malignancy can not be predicted from the 
histological findings (27, 45). In prostate cancer the 
degree of dedifferentiation forms the basis for the 
probability of metastatic spread and survival. Growth rate, 
metastatic potential and therapeutic responsiveness seem to 
be unpredictable for this tumor (12, 50). The majority of 
seminomatous and non-seminomatous testis tumors can be cured 
nowadays. Selection of treatment protocols is based on the 
histopathological classification, the presence or absence of 
residual disease following surgical or chemotherapeutic 
intervention, and on the extent of local disease (9, 12). 
In testis tumor classification, the pluri-potential nature 
of neoplastic germ cells must be taken into consideration 
(3Θ, 52). 
The aim of this thesis is to immunohistologically and 
cytologically investigate urological tumors in search for 
new diagnostic and prognostic factors. Especially 
cytoskeletal structures and nuclear desoxyribonucleic acid 
(DNA) contents in urological tissues and tumors were 
examined in order to obtain additional information about a 
tumors' biological characteristics besides the routine 
histopathological data. Factors such as heterogeneity of a 
certain tumor as well as its DNA content or the ploidy of a 
certain fraction of a tumor were examined in this way. 
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Recent developments in cell biology, biochemistry and 
cancer research have led to the identification and 
characterisation of the molecules that make up the cell 
matrix. These proteins form a highly structured yet 
changeable matrix in the cytoplasm and affect cell shape, 
cell division and motion as well as the transport of 
vesicles and organelles (2). This fibrous matrix of 
proteins spans the cytoplasm between the nucleus and the 
inner surface of the plasma membrane and plays an important 
role in the cell's vital processes. One group of 
cytoskeletal structures in particular has been shown to be 
important in the characterization of differences between 
different tissues and tumor types. These structures are 
formed by a distinctive set of proteins constituting the 
intermediate filaments (39). These intermediate filaments, 
have a diameter of 7 - 1 1 nm and can be visualized using 
specific antibodies. It was noticed that the intermediate 
filament proteins have a tissue specific distribution and a 
specific distribution pattern within the cell (39). 
Therefore antibodies to these proteins can be useful tools 
in histopathologic diagnostic procedures for the 
characterisation of specific cell types and in histogenetic 
studies, especially since these proteins are retained upon 
malignant transformation of cells (1, 11, 37, 42). 
In this thesis antibodies to intermediate filament 
proteins have been applied to specific problems in 
urological carcinogenesis. For example, in kidney tumors 
different intermediate filament types can occur 
simultaneously in the same tumor cell (24, 26). The study 
of this co-expression and its correlation with biological 
behaviour of the different cell compartments within a 
heterogeneously composed kidney tumor may lead to a better 
insight in the behaviour of such malignancies. Changes in 
the intermediate filament pattern in bladder tumors may 
occur during malignant progression (25, 43). The origin of 
prostate tumors and their development from specific 
epithelial cell subpopulations can be studied using 
antibodies to different intermediate filament proteins (Θ). 
A clear distinction between the two major groups of testis 
tumors can be made with the help of antibodies to 
intermediate filament proteins (4, 35). A study of these 
proteins in urological tissues and tumors can give more 
information about tumor histogenesis and cellular 
differentiation during malignant transformation. 
The search for pathognomonic features that discriminate 
malignant from benign cells is more than a century old and 
besides light microscopy, the quantitative assessment of 
cell features represents a possible methodology in 
diagnostic pathology (21). This can be used in the process 
of diagnosis and grading of tumors and prediction of 
subsequent biological progression. One of the major cell 
characteristics that may change upon malignant 
transformation is its nuclear DNA content. In this central 
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cell compartment, the basis of cell function is stored in 
the DNA structure and changes in this system, its structure 
or quantity can occur due to neoplasia (21). In a 
relatively simple staining procedure Propidium Iodide can be 
used for quantitative flow cytometric DNA content analysis 
with a high sampling rate. The advantage of using Propidium 
Iodide, which binds to the double stranded DNA, is the 
possibility to combine this dye with fluoresceine (FITC) 
labelled antibodies, allowing simultaneous analysis of DNA 
content and protein-antigens in a single beam flow cytometer 
(47). Large cell samples can be analysed at high speed when 
they are present as a disaggregated cell suspension. This 
is readily achieved with noncohesive malignancies such as 
leukemias or exfoliated cells in body fluids. 
Disaggregation procedures of solid tumors are possible but 
can give technical problems (6, 14). 
The application of flow cytometry to diagnostic 
pathology in general, as well as in the evaluation of 
urological disease in particular, have been described by 
several authors (7, 18, 23, 32, 34). In kidney tumors, a 
correlation with histological grading, heterogeneity and 
prognosis has been subject of several studies (3, 33, 40, 
46). Bladder tumors and urine samples have been extensively 
investigated in flow cytometry for a further 
subclassification of tumors, for monitoring patients' 
follow-up and as a possibility to detect prognostic factors 
(10, 13, 16, 19, 20, 28, 29, 30, 36, 49). The analysis of 
the relation between the degree of differentiation and DNA 
content may improve the prognostic evaluation of prostate 
cancer (17). In patients with a testis tumor, flow 
cytometric analysis of the semen has given additional 
information next to routine analysis of spermiogenesis (15). 
Therefore, it is obvious that flow cytometric analysis of 
tumors is a powerful tool in the management of cancer. 
In this thesis antibodies to intermediate filament 
proteins have been applied in diagnostic procedures of 
urological tumors as well as in flow cytometric analysis of 
urological cancers, in order to obtain more information 
about biologically important tumor cell characteristics. 
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INTERMEDIATE FILAMENT PROTEINS AS TISSUE SPECIFIC MARKERS 
IN NORMAL AND MALIGNANT UROLOGICAL TISSUES 
Immunocytochemical techniques have become valuable 
tools in many fields of clinical pathology and medical 
research. Especially the development of highly specific 
(monoclonal) antibodies to a large variety of tissue 
antigens has in recent years led to the establishment of 
sensitive tissue markers. One of the most promising types 
of tissue specific markers sofar is represented by the 
intermediate filament proteins. Since the findings of this 
rapidly expanding field are also being applied in urology, 
we have reviewed the current data in order to describe the 
new insights in tumor biology and histogenesis, as well as 
their application in diagnostic pathology. 
TISSUE SPECIFIC DISTRIBUTION OF INTERMEDIATE FILAMENT 
PROTEINS 
Intermediate filaments form a part of the intracellular 
cytoskeletal matrix present in all mammalian cells. These 
7-11 nm proteinaceous filament structures occur in cells in 
addition to microfilaments and microtubules. Figure 1 shows 
examples of the distribution and pattern of cytoskeletal 
structures, i.e. microtubules and intermediate filaments in 
cultured human bladder transitional cell carcinoma cell 
lines. 
Five types of Intermediate Filament Proteins (IFP) have 
been recognized and analysed by biochemical and 
immunohistochemical techniques (1, 2, 3). On the basis of 
these results the following correlations have been observed: 
1) Cells and tissues of mesenchymal origin contain vimentin 
as their IFF. 
2) Muscle tissues contain desmin IFP. 
3) Nervous tissues contain the neurofilament proteins. 
4) Glial cells contain intermediate filaments of the glial 
fibrillary acidic protein (GFAP) type. 
5) Cytokeratins constitute the intermediate filament system 
of epithelial cells. 
Nineteen different cytokeratin polypeptides have been 
characterized in human epithelial tissues so far. These can 
be further subdivided into the type I or acidic and type II 
or basic cytokeratins (3). These polypeptides are not 
expressed randomly throughout epithelia, but occur in 
cell-type specific combinations (1, 3). The cytokeratin 
patterns of epithelial tumors are either identical, or at 
least closely related to the cytokeratin pattern present in 
the cell of origin (1, 4). Several conventional antisera as 
well as monoclonal antibodies have been raised against IFP, 
and most of them have been shown to react in a tissue 
specific manner. Since normally IFP are retained in a cell 
upon malignant transformation, such antibodies can be 
exploited in surgical pathology to assist in the final tumor 
diagnosis (5, 6). Recent studies using monoclonal 
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antibodies to individual cytokeratin polypeptides have shown 
that such antibodies can distinguish between different types 
of epithelia (2, 7, 8). For example, an antibody to 
cytokeratin 1Θ mainly recognizes "simple" columnar epithelia 
but not squamous epithelia. On the other hand, a monoclonal 
antibody directed against the high mol. weight cytokeratins 
specific for epidermis stains only keratinizing squamous 
epithelial cells (2). Furthermore, tumors derived from 
these different types of epithelia can be distinguished and 
characterized using these monoclonal anticytokeratin 
antibodies (9, 10). 
The immunocytochemical evaluation of urological tumors 
using antisera to several IFF has produced two results. The 
first is the ability to make a more precise diagnosis in a 
number of difficult cases. 
At the level of individual patients' tumors, routine use of 
a selection of several anti-IFP antisera may lead to a 
revision or a new interpretation of a diagnosis which seemed 
highly likely on the basis of routine histology. 
The second result is the gaining of new insights into the 
biology and histogenesis of different tumor types. Routine 
application of multiple anti-IFP antisera to tumors which 
were thought to be reasonably well-defined on clinical and 
morphologic grounds provided potentially valuable new 
insights into the nature of these tumors. Furthermore, 
applying combinations of monoclonal and polyclonal 
antibodies to cytokeratins and other IFF's in normal and 
neoplastic tissues has demonstrated a considerable 
heterogeneity in IFP expression by tumors, especially those 
from the urogenital tract. These tissues and tumors will be 
described in more detail. 
NORMAL KIDNEY AND ITS TUHORS 
In order to fully understand IFP staining patterns in 
malignant neoplasms, it is of great importance to examine 
their normal tissue counterpart(s) or their most likely 
cells of origin in order to investigate differences occuring 
during malignant transformation. Furthermore, knowledge of 
changes occurring in IFP distribution during embryologie 
differentiation can give important clues about staining 
patterns recognized in poorly differentiated tumors. Frozen 
sections from normal monkey-, rat- and human kidneys (Fig. 
2a-d) were examined with antibodies to skin keratins (11), 
vimentin (6), desmin (12) and different types of monoclonal 
antibodies to cytokeratins (2, 9, 13, 14). It was seen that 
collecting tubule epithelium and parietal epithelial cells 
on Bowman's capsule are positive for keratin when incubated 
with a polyclonal serum to skin keratins. Also cells of 
some distal convoluted tubules show a basal positivity. 
Additionally, when incubated with the monoclonal antibodies 
to cytokeratin 18, proximal and distal convoluted tubules as 
well as the loops of Henle are positive (Fig.2b). 
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Figure 1 Immunofluorescence micrographs of human bladder 
carcinoma cells in culture showing the cytoskeletal 
structures present in these cells. (a) microtubules, (b) 
cytokeratin intermediate filaments and (c) vimentin 
intermediate filaments (a, b, c: x350). 
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Similar results were found with a monoclonal cytokeratin 
antibody (RCK102) recognizing virtually all types of 
epithelia (Fig.2a). On the other hand a monoclonal antibody 
specific for cytokeratin 7 stains only the large distal 
collecting ducts of the kidney and parietal epithelial cells 
on Bowman's capsule (Fig.2c). These findings are in 
accordance with those of Holthoefer et al. (15, 16), 
Bachman et al. (17) and Achtstaetter et al. (18). These 
latter authors have demonstrated the expression of 
cytokeratin polypeptides 7, 8, 18 and 19 in renal tubules 
and collecting ducts of the kidney. Our immunofluorescence 
data using the monoclonal antibody to cytokeratin 7 clearly 
show that this polypeptide is absent in most kidney tubules 
with the exception of the large collecting ducts. These 
findings do not support the proposition made by Holthoefer 
et al. (15) on the basis of their studies with cytokeratin 
antibodies that parietal cells of Bowman's capsule represent 
a continuation of the proximal tubular cells. With the 
polyclonal antibody to vimentin the mesangium and 
endothelium of the glomerulus are stained (Fig.2d). The 
parietal epithelium seems to show variable staining with 
vimentin antibodies and also occasionally we observed faint 
vimentin positivity in some of the distal convoluted 
tubules. This co-expression of cytokeratin and vimentin 
deserves further investigation. In this context it is 
interesting to note that Holthoefer et al. (15, 16) have 
observed a transient co-expression of vimentin and 
cytokeratin in collecting ducts of fetal kidneys. 
Connecting tissue fibroblasts, endothelium, and smooth 
muscle cells in blood vessels are also positive for 
vimentin. In our experiments, desmin was only found in the 
smooth muscle cells of the blood vessels. 
Bachman et al. (17) have shown co-existence of vimentin and 
desmin in glomerular and extra-glomerular mesenchymal cells, 
which is in agreement with the notion that these cells are 
derived from a specific subset of vascular smooth muscle 
cells (19). 
Renal cell tumor (Grawitz tumor) 
Renal cell carcinoma (Grawitz tumor) is a malignant 
tumor of kidney cells. Since its initial description, the 
origin and nature of this tumor has been controversial (for 
review see 20). However, in recent years it has become 
clear that it is in fact a primary tumor probably arising 
from proximal tubular epithelial cells. It has been 
considered an adenocarcinoma because of its light and 
electron microscopic features, especially the presence of 
intercellular bridges and the formation of ducts and 
gland-like structures. However, the clinical behaviour of 
this tumor was never totally supportive of the 
interpretation that it is a simple adenocarcinoma. Two 
features of the clinical behaviour of this tumor which 
suggest a more complicated interpretation are its marked 
tendency to early blood vessel invasion and lung metastasis 
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as well as a noteworthy resistance to chemotherapy, both 
features of sarcomas. Routine use of anti-IFP antibodies in 
evaluating renal cell tumors of adults has shown that these 
tumors usually contain both cytokeratins and vimentin. 
Individual cells with both IFP types are routinely 
demonstrable in renal cell tumors (15, 21). We have found 
that most of the tumors examined (37 out of 40) express 
vimentin in virtually all cells. Cytokeratins are expressed 
to a lesser extent in the tumors. In this respect double 
immunofluorescence labelling demonstrated that some of the 
vimentin containing cells co-expressed cytokeratin (Fig.2e, 
f), while others did not. However, also occasionally tumor 
cells were found to contain cytokeratin but not vimentin. 
Some lymph node metastases were found to express only 
vimentin or cytokeratins. In summary we find higher 
percentages of tumors co-expressing vimentin and cytokeratin 
than described by Holthoefer et al. (15) who found 
simultaneous expression of both types of intermediate 
filaments in only about half of their samples. On the basis 
of these findings, we have proposed that renal cell tumors 
may better be considered carcinosarcomas than pure 
adenocarcinomas (21). This interpretation of the biology of 
renal cell tumors fits well with both the clinical course 
and the immunopathologic findings. Using the polypeptide 
specific monoclonal antibodies directed against subtypes of 
cytokeratins we found cytokeratin 18 but not cytokeratin 7 
in most tumors examined. These data confirm results 
described by Achtstaetter et al. (18) who could demonstrate 
cytokeratins 8, 18 and 19 in kidney tumors using biochemical 
techniques. The absence of cytokeratin 7 both in normal 
proximal tubules and in renal cell tumors supports the 
assumption that such malignancies may be derived from 
proximal tubular epithelium. 
Nephroblastoma (Wilms' tumor) 
Unlike its adult counterpart, the nephroblastoma's 
origin as a renal tumor has been recognized from the first 
descriptions of this tumor, since the three cell types which 
comprise the tumor are easily recognized as malignant 
counterparts of the cells and structures forming the kidney 
during embryological development. Recent studies of 
nephroblastoma using antibodies to IFP's (Fig.2g, h) have 
shown that, similar to its adult counterpart, nephroblastoma 
contains both vimentin and cytokeratin, with co-expression 
of both IFP's in some of the tumor cells (13, 22). 
Immunofluorescence microscopy studies revealed expression of 
cytokeratins and vimentin in blastema cells, while tubules 
were only labelled by the cytokeratin antibodies (13, 22, 
23). In undifferentiated nephroblastomas with absence of 
tubule formation, the blastema cells were only vimentin 
positive and cytokeratin negative. We have found that part 
of the tubules are positive using monoclonal antibodies to 
cytokeratins 7 and 18, which is in accordance with the 
suggestion of Yeger et al. (23) that Wilms' tumor tubules 
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more closely resemble distal than proximal convoluted 
tubules of adult kidneys. Vogel et al. (24) have described 
that rhabdoid tumors of the kidney contain both vimentin and 
cytokeratin. Occasionally we have observed desmin positive 
cells in nephroblastomas in the myoid component. From this 
point of view it is therefore interesting to note the almost 
perfect separation of patients with one of the two types of 
a kidney tumor. The peak incidence of nephroblastoma is in 
the preschool years with very few well-documented cases 
occuring after the age of 20. Conversly, well-documented 
cases of pure Grawitz tumor before the age of 20 are quite 
unusual. 
The demonstration that both childhood and adult primary 
renal tumors have an important biological property in 
common, namely expression of both vimentin and cytokeratin 
IFF has focused attention on abnormalities of these tumors 
heretofore difficult to explain. Both tumors in addition to 
carcinomatous components frequently contain elements which 
histologically and ultrastructurally are sarcomatous (20). 
The presence of areas of adult type (Grawitz) renal tumor in 
otherwise typical nephroblastomas of young patients has been 
reported in the U.S. National Wilms Tumor Study (25). 
Finally, nephroblastoma shows two variants, clear cell 
sarcoma of the kidney and malignant rhabdoid tumor of the 
kidney. These are both relatively more aggressive neoplasms 
than the usual nephroblastoma. 
Figure 2 Immunofluorescence micrographs of normal kidney and 
kidney tumors stained with IFF antisera. (a-d) Normal 
kidney frozen sections incubated with the monoclonal 
cytokeratin antibody (RCK102) recognizing all epithelial 
cells (a), the monoclonal antibody to cytokeratin 18 (RGE53) 
staining the proximal and distal convoluted tubules and the 
loops of Henle as well as large distal collecting ducts and 
the parietal epithelial cells on Bowman's capsule (b). The 
monoclonal antibody specific for cytokeratin 7 stains only 
parietal epithelial cells and large collecting ducts (c). 
With the antibodies to vimentin the mesangium and 
endothelium of the glomerulus are stained (d). (e-f) Human 
kidney tumors incubated with cytokeratin and vimentin 
antibodies. (e, f) Double immunofluorescence labelling 
demonstrates the co-expression of cytokeratin (e) and 
vimentin (f) in renal cell (Grawitz) tumor. (g, h) 
Co-expression of cytokeratin (g) and vimentin (h) is also 
found in tubular structures of nephroblastoma. Blastema 
cells react only with the vimentin antibody. (i-1) Renal 
tumor model systems. Co-expression of cytokeratin (i, k) 
and vimentin (j, 1) was also found in a xenograft of a renal 
cell (Grawitz) tumor (i, j), as well as in a rat renal cell 
tumor (k, 1) (a-f and i-1: xl50; g, h: x325). 
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In addition, clear cell sarcomas, which have been shown to 
contain vimentin IFP (22), have a marked propensity for bone 
metastases. Thus, prompted by the immunopathological study 
of IFP expression in both childhood and adult renal cell 
tumors, an unifying concept of these tumors emerges. Both 
Wilms' and Grawitz tumor may be considered carcinosarcomas, 
since they express epithelial as well as mesenchymal 
properties. Both in children and adults an unbalanced 
proliferation of elements differentiated more along 
epithelial lines or more along mesenchymal lines leads to 
the bewildering variety of tissue types seen in these 
tumors. Finally, this interpretation of the biology of 
renal cell tumors correlates well with the clinical 
behaviour of these tumors as mentioned above. 
Renal tumor model systems 
Frozen sections of xenografts of human renal cell 
tumors in nude mice (Fig.2i, j) and a rat renal cell tumor 
(Fig.2k, 1) could also be shown to contain cytokeratins and 
vimentin (26). In double labelling studies it was seen that 
vimentin positive cells were also positive for cytokeratin. 
This may give support to the suggestions that these 
experimental tumors may be used as proper renal cell tumor 
model systems for further biological and chemosensitivity 
studies. 
NORMAL AND NEOPLASTIC UROTHELIUM 
The normal mucosal lining of the urinary tract between 
the renal pelvis and the urethra, the transitional 
epithelium, is a thin tissue composed of 5-7 cell layers. 
The cells composing the deeper layers show little 
morphologic or functional differentiation until they reach 
the luminal surface. Here the amount of cytoplasm increases 
significantly and the cells assume the shape of umbrella 
cells, responsible for maintaining the water-tightness of 
the urinary tract. In normal adult and embryological 
transitional cells only IFP of the cytokeratin type have 
been detected (27, 28). Using a polyclonal rabbit antiserum 
to skin keratins or the broadly cross-reacting monoclonal 
cytokeratin antibody (RCK102) all layers of the bladder 
epithelium were stained (Fig.За, c). Biochemical and 
immunohistochemical studies using polyclonal and monoclonal 
antibodies have demonstrated the presence of cytokeratins 
nrs 7, 8, 18 and 19 with small amounts of cytokeratins 4 and 
5 in this type of epithelium (10, 18, 27, 28, 29). 
Interestingly, several authors have found that certain 
monoclonal antibodies specific for cytokeratin 18 stain only 
a subset of transitional epithelial cells i.e. the umbrella 
cells (see Fig.3b, d and references 18, 28, 29). However, 
other monoclonal antibodies specific for this cytokeratin 
subtype recognize all cell layers of the urothelium (8, 18). 
A possible explanation for this phenomenon would be the 
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selective unmasking of certain cytokeratin 18 epitopes as a 
result of urothelial cell differentiation. 
In addition to these findings it is of importance to note 
that Summerhayes and Chen (27) have shown in mouse bladder 
epithelium the presence of a 52 kD cytokeratin which occured 
exclusively in the basal epithelial cell layer, but seemed 
to be absent in the intermediate and superficial layers. 
Transitional cell carcinoma 
The simplest neoplastic growth in transitional 
epithelium, the flat carcinoma in situ, is a replacement of 
normal transitional cells by cells with features of 
malignant cells, i.e. increased nuclear/cytoplasmic ratio, 
irregular nuclear and chromatin features, etc. Development 
of non-invasive papillary transitional cell tumors is 
characterized by the formation of papillary fronds 
projecting into the lumen of the urinary tract. These 
fronds have a thin connective tissue stalk containing blood 
vessels and are lined on the outside by more or less 
abnormal transitional epithelium. These non-invasive 
papillary transitional cell tumors are graded according to 
both histologic and cytologic criteria. The best 
differentiated papillary tumors (Grade 0; papilloma) show a 
lining epithelium on the papillary surface which is composed 
of cells and tissue structures identical to normal 
transitional epithelium. 
Increasing dedifferentiation of these papillary tumors 
(Grades 1 to 3)- is marked both by increasing thickness of 
the epithelium caused by increased numbers of cells and by 
increasing cellular atypia. Thus grade 3 papillary 
transitional cell carcinomas show a marked increase in the 
number of cell layers in the frond-lining epithelium and 
most of these cells have nuclear and cytoplasmic features of 
carcinoma cells. The third form of neoplastic growth in 
transitional epithelium is frankly invasive carcinoma. 
However, these carcinomas may be composed of cells with more 
or less malignant features and are therefore also graded 1 
to 3, grade 3 being the most malignant-appearing cell type. 
As a consequence of the complex relationship of cytologic 
and histologic dedifferentiation in transitional cell 
neoplasia, grading of the lesions provides relatively less 
insight into the expected tumor behaviour than grading of 
many other carcinomas. This is especially true at the level 
of the individual patient's prognosis. 
The study of IFF expression in neoplastic transitional 
epithelium has provided new insights into the nature and 
progression of carcinogenesis in this tissue. Cytokeratins 
7, 8 , 18 and 19 can readily be detected in these tumors by 
gel-electrophoretic and immunocytochemical techniques. In 
addition to these, cytokeratins 5, 13 and 17 were found in 
some tumors (18). Athough all cell layers of neoplastic 
transitional epithelium express cytokeratin as recognized by 
several cytokeratin antibodies (Fig.3e, g and 28), 
Page 30 
application of one of the monoclonal antibodies to 
cytokeratin 1Θ (RGE53) shows an interesting series of 
changes associated with neoplastic progression. In 
non-invasive papillary transitional cell carcinomas, the 
tumors which appear cytologically and histologically well 
differentiated (Grades 0 and 1) show a pattern of 
cytokeratin 18 expression similar to that of normal 
urothelium with only the most superficial cell layer 
reacting with the cytokeratin 18 antibody (Fig.3f). 
Somewhat less differentiated tumors with an increased 
cellular atypia (Grade 2) begin to show single cells and 
small clusters of cells deeper in the epithelium which 
express this specific cytokeratin 18 epitope. The least 
differentiated most atypical invasive tumors (Grade 3) show 
cytokeratin 18 positive cells throughout the whole thickness 
of the epithelium (Fig.3h). In a lymph node metastasis all 
transitional epithelial tumor cells showed reactivity with 
this cytokeratin 18 antibody (30). From these findings it 
appears that both during urothelial cell differentiation and 
during its neoplastic progression similar alterations in the 
epitope availability of the cytokeratin 18 protein occur. 
These findings are especially striking since transitional 
cell neoplasia seems to consist of morphologically less 
differentiated cells, analogous to those comprising the 
basal and parabasal cell layers of normal transitional 
epithelium, rather than the more differentiated umbrella 
cells of the epithelial surface. 
Figure 3 Immunofluorescence micrographs of normal human 
bladder and bladder tumors. (a-h) Embryonal human bladder 
tissue stained with a polyclonal cytokeratin antibody (a), 
and an antibody specific for cytokeratin 18 (RGE53) (b). 
(c-d) Normal adult bladder epithelium stained with the 
polyclonal antibody (c) and with the monoclonal antibody to 
cytokeratin 18 (RGE53) (d). (e-h) Low grade, low stage 
transitional cell carcinoma (TCC) (e, f) and a high grade, 
high stage TCC (g, h) stained with the polyclonal 
cytokeratin antibody (e, g) and the monoclonal antibody to 
cytokeratin 18 (RGE53) (f, h). Note the increase of the 
relative number of RGE53-positive cells upon neoplastic 
progression. (i) The presence of squamous cell 
differentiation in TCC can be recognized by a monoclonal 
antibody specific for keratinizing stratified epithelium. 
(j-1) BBN induced bladder tumors in the rat which show a 
similar staining pattern as for the human bladder tumors in 
small lesions (j, k), (j: polyclonal cytokeratin antiserum; 
k: monoclonal antibody RGE53) but with increasing 
malignancy demonstrate predominance of squamous elements as 
detected by the monoclonal antibody specific for 
keratinizing cells (1) (a-b: xl30; c-1: xl50). 
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This reactivity pattern may be useful for a better 
classification of transitional cell carcinomas (28, 30, 31). 
In some cases of bladder carcinoma we have observed small 
numbers of cells reactive with a monoclonal antibody 
specific for keratinizing stratified epithelial tissues 
(Fig.3i). This suggests the presence of small areas with 
squamous cell differentiation or single cells keratinizing 
within these tumors. 
Bladder tumor model systems 
In the examination of rat bladders bearing tumors 
induced by butyl-(4-hydroxybutyl)-nitrosamine (BBN) by 
routine histology and immunohistochemical staining of 
intermediate filament types (32) smaller lesions were 
stained similar to human urothelial dysplasia (Fig.3j, k). 
Progression of the lesions demonstrated large exophytic 
papillomas with extensive endophytic epithelial growth into 
abundant stroma. These lesions showed increasing 
predominance of squamous over transitional elements. 
Immunohistochemical findings confirmed these results and 
also demonstrated that morphologically indifferent cells, 
even in early lesions, express cytokeratin 10, 
characteristic of keratinizing squamous epithelium (Fig.31). 
These results demonstrate that BBN-induced bladder tumors 
show marked quantitative and qualitative differences from 
the most common, purely transitional, human bladder 
carcinomas. Summerhayes and Chen (27) concluded from a 
similar study using an antibody to a 52 kD cytokeratin 
polypeptide that BBN-induced hyperplastic bladder lesions in 
mice result primarily from the proliferation of cells in the 
basal compartiment. They also found that this antibody, 
which in normal mouse bladder only stained the basal cell 
layer, reacted homogeneously with all squamous cell 
components, whereas the transitional cell component showed 
mainly reaction in the basal cells of the epithelial 
islands. Hasegawa and Cohen (33) have also suggested 
changes in cytokeratin expression in proliferative rat 
bladder lesions. All in all, these studies strongly 
indicate that the cytokeratin composition and/or 
distribution in the bladder urothelium changes following 
induction of carcinogenesis. 
NORMAL AND NEOPLASTIC PROSTATE TISSUE 
In normal and hyperplastic prostate tissue, a clear 
distinction can be made between the epithelial and the 
stromal cell component with the help of cytokeratin and 
vimentin antibodies (compare Fig.4a and e), although 
occasionally some co-expression of both types of IFP is 
found in the columnar epithelium (Fig.4e). With a rabbit 
antiserum to human skin keratins a strong reaction is seen 
in the basal cells (Fig.4a) with a weak staining of the 
columnar epithelium. Similar observations have been made by 
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Achtstaetter et al. (18) when using a guinea pig antiserum 
to epidermal keratins. The monoclonal cytokeratin antibody 
RCK102, which stains virtually all epithelia, reacts equally 
strong with both basal and columnar cells (Fig.4b). Brawer 
et al. (34) have described a monoclonal cytokeratin 
antibody (recognizing several keratins from human stratum 
corneum) which in prostate specifically recognized basal 
cells of the glandular ducts (see also 35). A similar 
staining pattern found with the monoclonal cytokeratin 
antibody RCK103, is shown in Fig.4c. On the other hand, 
monoclonal antibodies to cytokeratin 18 can be shown to 
react only with normal and hyperplastic columnar (secretory) 
epithelial cells (Fig.4d and reference 18). It can 
therefore be concluded that cytokeratin expression differs 
among the epithelial cell populations of the human prostate. 
Prostate tumors 
When prostate tumors of several degrees of malignancy 
(well-differentiated adenocarcinoma to anaplastic prostate 
carcinoma) were tested with different monoclonal cytokeratin 
antibodies, virtually all tumor cells were stained with the 
broadly cross-reacting cytokeratin antibody RCK102. The 
rabbit antiserum to skin keratin, however, gave only a weak 
to negative reaction in the tumor cells (Fig.4f, h). 
Similary, the monoclonal antibody RCK103 recognizing only 
basal cells in normal and hyperplastic prostate, also showed 
a negative or occasionally weak reaction in the tumor cells. 
On the contrary, the monoclonal antibody to cytokeratin 18, 
which reacted strongly with the "normal" columnar epithelial 
cells, also gave a strong positive reactivity pattern in 
virtually all tumor cells (Fig.4g, i). Therefore we, in 
accordance with Brawer et al. (34), conclude that the 
differential staining pattern of the (monoclonal) 
cytokeratin antibodies available sofar may assist in 
distinguishing hyperplastic from neoplastic prostate 
epithelium, as well as in the recognition of basal cell 
hyperplasia, transitional cell metaplasia and premalignant 
changes. We can conclude from our data and those from 
Brawer et al. (34), that prostatic intraepithelial 
neoplasia may arise directly from the columnar (secretory) 
epithelial cells or that the cytokeratin profile changes 
during malignant transformation of the prostate basal cell 
layer. 
Prostate tumor model systems 
Prostate tumor model systems include in vitro systems, 
spontaneously occuring tumors, spontaneously transplantable 
tumors, chemically or hormonally inducible tumors and 
xenografts (36, 37, 38). One of the model systems that has 
been investigated elaborately is the Dunning rat prostatic 
tumor model system. This system comprises a spectrum of 
different types of prostatic tumors with varying degrees of 
malignancy or biological behaviour. One of the most 
Page 34 
malignant and highly metastatic sublines within this system 
is comprised by the MATLyLu tumor (39). Immunohistochemical 
investigation of frozen sections from MATLyLu subcutaneous 
tumors as well as from lymph-node metastases showed a 
slightly positive reaction with the polyclonal cytokeratin 
antibodies and a moderate to strong reaction to the vimentin 
antibodies. This pattern contrasts with the strong reaction 
to the monoclonal antibody to cytokeratin 18 seen in this 
tumor line. Co-expresion of vimentin and cytokeratin IFP 
was seen in the same cells using double label 
immunofluorescence (Fig.4j, k). Similar observations were 
made in tissue cultures of this tumor (Fig.41, m). These 
data suggest that the MATLyLu tumor may originate from the 
columnar glandular epithelial cell layer in rat prostate. 
Figure 4 Immunofluorescence micrographs of benign and 
malignant prostatic tissues stained with antibodies to 
cytokeratins and vimentin. Strong reactivity in the basal 
cell layer and a weak staining of the columnar epithelial 
cells of human benign prostate tissues is seen with the 
polyclonal antiserum to skin keratins (a). Both the basal 
cell layer and the columnar epithelial cell layer are 
stained equally strong with the monoclonal antibody RCK102 
(b). The basal cell layer can be stained specifically with 
the monoclonal cytokeratin antibody RCK103 (c), whereas the 
columnar epithelium can be stained specifically with the 
antibody to cytokeratin 1Θ (RGE53) (d). The stromal 
component is stained with vimentin antibodies (e). 
Occasionally vimentin expression is seen in the columnar 
epithelium (e). (f-i) In well-differentiated (f, g) and 
anaplastic (h, i) prostate tumors a weak staining pattern 
can be seen in the tumor cells with the polyclonal keratin 
antiserum (f, h) in contrast to a strong reaction pattern 
with the monoclonal antibody to cytokeratin 1Θ (g, i). 
(j-m) The rat prostate tumor model system MATLyLu. The 
epithelial origin of this tumor is recognized by the 
expression of cytokeratin intermediate filaments (j) but as 
a result of multiple passages from one animal to an other 
this tumor shows co-expression of vimentin (к). Similar 
observations were made in tissue cultures of this tumor (1: 
cytokeratin; m: vimentin) (a-k: xlSO? 1, m: x320). 
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NORMAL AND NEOPLASTIC TESTIS TISSUE 
When frozen or paraffin sections of normal human testis 
(Fig.5a-f) are incubated with the antisera to cytokeratin, a 
strong positive reaction is only seen in the epithelial 
cells lining the ductus efferens and the rete testis 
(Fig.5e). No other cell types are positive for cytokeratin 
(Fig.5a), except for one case were we have found some 
cytokeratin positive cells in the seminiferous tubules 
(Fig.5b). This case, however, represented testis tissue in 
which spermatogenesis was lacking because of the presence of 
a tumor. Similar observations have been described by 
Miettinen et al. (40) and by Damjanov et al. (41) for 
intratubular atypical ("carcinoma in situ") cells in 
embryonal carcinoma bearing testis. From the use of 
cytokeratin-polypeptide-specific monoclonal antibodies 
described above and two-dimensional gel electrophoresis (1Θ) 
it can be concluded that the cells lining the rete testis 
contain cytokeratins 7, 8, 18 and 19 while the epithelium of 
the ductus efferens in addition contains cytokeratin 5. 
According to Achtsteater et al. (18), the epididymis, 
ductus deferens and seminal vesicles also contain 
cytokeratins 5, 7, 8, 18, 19 and may contain cytokeratin 17. 
The antibodies to vimentin do not stain the epithelial 
cells of the ductus efferens. Strikingly, however, a 
considerable percentage of the epithelial cells of the rete 
testis were also positive for vimentin (Fig.Sf). 
Figure 5 Immunofluorescence micrographs of normal and 
malignant testis tissues. (a-f) Normal human testis shows 
strong positive reaction with cytokeratin antibodies in the 
epithelial cells lining the ductus efferentes and rete 
testis (e) and except for occasionally positive cells in 
some seminiferous tubules (b) no other cells are cytokeratin 
positive (a). A vimentin positive reaction is found in 
Sertoli and Leydig cells (c). Myoid cells surrounding the 
seminiferous tubules were strongly positive with the 
antibodies to desmin (d). Co-expression of cytokeratin (e) 
and vimentin (f) can be seen in the epithelial cells of the 
rete testis (e, f) and classic and anaplastic seminomas are 
positive for vimentin (h) and negative for cytokeratin (g) 
although a few cytokeratin positive cells can occasionally 
be seen in such tumors. Non-seminomatous testis tumors such 
as embryonal cell carcinomas show a positive reaction with 
cytokeratin antibodies in the tumor cells (i) but not with 
the vimentin antibodies (j), which stain only the stromal 
component. In teratocarcinomas (k, 1) a differentiation can 
be made between the glandular and squamous components using 
a monoclonal antibody to cytokeratin 18 (1) in combination 
with the polyclonal keratin antiserum (k) (a-1: xl50). 
Page 37 
Page 38 
Double-labelling experiments clearly proved this 
co-expression of cytokeratin and vimentin in rete testis 
lining epithelial cells (compare Fig.Se and 5f and see 
reference 42). Also in the cytokeratin positive cells 
present in the seminiferous tubules described above, 
co-expression of cytokeratins and vimentin was seen (not 
shown). Furthermore, a positive reaction with the vimentin 
antibodies is found in Sertoli cells and in Leydig cells 
(Fig.5c). The Leydig cells, however, showed a variable 
reaction, with some cells negative for vimentin and others 
containing perinuclear clusters of this antigen. 
Fibroblasts and blood vessels were also stained with the 
antivimentin antibody. We could not find any staining 
reaction with any of the antibodies in spermatozoa. 
Virtanen et al. (43) however could show that human 
spermatozoa have a highly specialized cytoskeletal 
organization with vimentin forming band-like structures in 
the sperm head. 
Myoid cells surrounding the seminiferous tubules were 
strongly positive with the antibodies to desmin (Fig.5d). 
Some of these myoid cells could be shown to co-express 
desmin and vimentin as demonstrated in the double-label 
indirect immunofluorescence technique (42). The desmin 
antibodies did not stain any other cell types than muscle 
cells. Neurofilament antibodies stained only nerve cells. 
Seminomas 
Classic seminomas, anaplastic seminoma in the testis 
and metastases of anaplastic seminomas are positive for 
vimentin. This staining reaction is, however, usually 
observed in a variable number of the tumor cells (Fig.5h). 
Identical results are obtained with monoclonal and 
polyclonal vimentin antibodies. When incubated with 
polyclonal or monoclonal antibodies to cytokeratins almost 
all cases are negative (Fig.5g and references 42 and 44), 
although in some of these cases few cytokeratin positive 
cells scattered through the tumor tissue sections were seen 
(40, 42). In a lymph node metastasis which was 
morphologically a pure anaplastic seminoma, a considerable 
fraction of cytokeratin positive cells was detected. This 
correlated well with the finding that the primary tumor in 
the testis was a mixed Yolk-sac tumor/seminoma (42). 
Interestingly, in one of the cases classified as 
seminoma that we have examined which had, however, elevated 
levels of the serum tumor markers alpha foetoprotein and 
beta HCG, it was obvious that some of the tumor cells were 
positive for cytokeratin. This immunohistochemical finding 
therefore confirmed the clinical diagnosis of a non-seminoma 
testis. 
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Non-seminomatous testis tumors 
Non-seminomatous testis tumors, including primary and 
metastatic embryonal cell carcinomas, primary and metastatic 
endodermal sinus tumor, choriocarcinomas and 
teratocarcinomas react with cytokeratin antibodies but not 
with vimentin antisera (40, 42, 44). Only stromal 
components of the tumor were positive for vimentin. 
Double-label immunofluorescence microscopy shows that the 
vimentin and cytokeratin reaction pattern are mutually 
exclusive in these tumors (compare Fig.Si, j). Different 
types of epithelial differentiation in teratocarcinomas can 
be identified using the different monoclonal cytokeratin 
antibodies (42). For example, with a monoclonal antibody to 
cytokeratin 18 (RGE53) a distinction can be made between the 
glandular and the squamous component of the tumor (Fig.5k, 
1). Haugen and Taylor (45) and Trojanowski and Hickey (46) 
have shown the presence of neural IF (neurofilaments and 
GFAP) in teratomas. Detection of these IFP in such testis 
tumors can be useful in their diagnosis, subclassification 
and investigation of their histogenesis and potentials of 
differentiation. 
Based on these studies we conclude that intermediate 
filament typing of testis tumors provides a useful adjunct 
to routine histology and determination of serum markers in 
determining therapy and prognosis, especially in cases of 
anaplastic tumors. 
Testis tumor model systems 
Extensive studies have appeared with respect to 
teratocarcinoma model systems (see for example reference 
47). The primary focus of these studies has been 
differentiation rather than oncology. Thus little 
information is available on the suitability of these model 
systems for studies of therapy and prognosis. 
CONCLUSIONS 
From the foregoing it may have become clear that the 
study of IFP expression in normal and neoplastic tissues of 
the urogenital tract is of exceptional interest, especially 
since it has produced important new insights in both 
fundamental cell biological and clinical aspects of this 
system. 
We have summarized current knowledge on this subject and 
shown that antibodies to IFP are important 
imraunohistochemical reagents in the study of histogenesis 
and differentiation of urogenital tract tissues. Moreover, 
these antibodies are useful tools in tumor grading and tumor 
classification. 
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ABSTRACT 
Thirteen primary and metastatic testicular germ cell 
tumors, including classical and anaplastic seminomas, and 
non-seminomatous testicular tumors were examined for their 
intermediate filament protein (IFF) types. The seminomas 
were shown to react with a monoclonal and a polyclonal 
antibody to bovine lens vimentin, while non-seminomatous 
germ cell tumors were strongly positive for a polyclonal and 
a monoclonal antibody to cytokeratin. 
In one case of seminoma with elevated serum levels of 
beta-HCG and alpha-FP, cytokeratin positive tumor cells were 
found. 
In the case of teratocarcinoma, several components of the 
tumor could be distinguished using a combination of antisera 
in double-label immunofluorescence microscopy. The 
glandular component of this tumor was positive with the 
polyclonal antikeratin, but also with the monoclonal 
cytokeratin antibody specific for glandular epithelia (RGE 
53). However, the squamous component was negative with this 
latter antibody. Strikingly, the spindle cell component 
showed focal positivity for vimentin, with co-expression of 
cytokeratin and vimentin in some cells. 
Our data show that antibodies to cytokeratin and vimentin 
can be helpful in the diagnosis of testicular germ cell 
tumors, especially in the differentiation between seminomas 
and non-seminomatous testis tumors. 
INTRODUCTION 
Identification of the intermediate filament protein 
types in cells of an unknown tumor offers the opportunity to 
obtain more information about its origin and nature (for 
reviews see Osborn and Weber, 1983; Ramaekers et al., 
1983a). Antisera specific for intermediate filament 
proteins have proven to be useful immunohistochemical tools 
in surgical pathology especially in those cases where 
routine histological techniques do not permit a clear cut 
(differential) diagnosis. For example, antibodies to 
cytokeratins and vimentin can be used to differentiate 
between anaplastic carcinomas and lymphomas or melanomas 
(Gabbiani et al., 1981; Altmannsberger et al., 1982a; 
Schlegel et al., 1980; Ramaekers et al., 1983b,c, 1985a), 
while an antibody to desmin allows a distinction between 
rhabdomyosarcomas and leiomyosarcomas from other soft tissue 
tumors (Altmannsberger et al., 1982b; Denk et al., 1983). 
Cytokeratins, the epithelial type of intermediate filament 
proteins, comprise a family of 19 closely related, though 
biochemically distinct, polypeptides which to a certain 
extent are distributed in a tissue specific manner 
throughout human epithelia (Moll et al., 1982). As a result 
monoclonal antibodies to distinct cytokeratin polypeptides 
have been shown to distinguish between different types of 
epithelia using immunohistochemical techniques (Lane, 1982; 
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Tseng et al., 1982). For example, antisera to cytokeratin 
18 recognize glandular epithelia and not squamous epithelia 
(Debus et al., 1982; Ramaekers et al., 1985b). Such 
monoclonal antibodies also distinguish adenocarcinomas from 
squamous cell carcinomas (Debus et al., 1984; Ramaekers et 
al., 1983d). 
The present report describes the use of monoclonal and 
polyclonal antibodies to the intermediate filament proteins 
vimentin and the cytokeratins in the diagnosis of primary 
and metastatic testicular tumors. Our findings show that 
such antibodies can distinguish seminomas from 
non-seminomatous tumors which may be helpful in surgical 
pathology, especially in those cases where the tumor cells 
exhibit an anaplastic appearance. 
MATERIALS AND METHODS 
In addition to a panel of human malignant tumors used 
to test further the monoclonal vimentin antiserum we 
investigated seven samples of seminomas and seminoma 
metastases, and six cases of non-seminomatous testicular 
tumors, both primary and metastatic. Table 2 summarizes the 
relevant clinicopathological data of the tumors 
investigated. Furthermore, we have investigated the 
intermediate filament distribution in five normal human 
testes, which were removed on clinical indications. 
A portion of each tumor was fixed in formalin, embedded in 
paraffin and used for routine histology using H&E staining. 
A second portion was frozen in liquid nitrogen immediately 
after surgery and either stored in liquid nitrogen or cut 
immediately into frozen sections. 
Immunohistochemistry 
Frozen tissue material was cut on a cryostat and 5-7 um 
thick frozen sections were fixed with methanol (-20 C, 5 
min) and acetone (roomtemp., 10 to 30 sec) or in acetone 
alone (5 min). 
Air dried sections were either rehydrated with phosphate 
buffered saline (PBS) or used directly for incubation with 
the first antiserum. Incubation procedures for single and 
double labeling indirect immunofluorescence have been 
described before (Ramaekers et al., 1981, 1982, 1983d,e) as 
has the immunoperoxidase (PAP) staining method used for the 
four cases of paraffin embedded normal testis (Ramaekers et 
al., 1983a). 
The following antibody preparations were used in this study: 
(1) An affinity purified antiserum to human callus keratins 
(pKer) raised in rabbits and affinity-purified on human 
keratins. The serum was diluted 1:10 to 1:20 for 
immunofluorescence and 1:50 for immunoperoxidase assays. 
For preparation and specificity testing see Ramaekers et 
al., (1982, 1983a,b). 
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(2) The mouse monoclonal antibody RGE 53 (available from 
Euro-Diagnostics B.V., Apeldoorn, The Netherlands) specific 
for cytokeratin 1Θ. Preparation and specificity testing of 
this antibody have been described (Ramaekers et al., 1983d). 
(3) An antiserum to calf lens vimentin (pvim), raised in a 
rabbit. Preparation and specificity of this antiserum have 
been described (Ramaekers et al., 1981, 1983a,с). 
(4) A monoclonal antibody to calf lens vimentin (MVI). The 
antiserum can be purchased from Euro-Diagnostics B.V., 
Apeldoorn, or Sanbio B.V., Uden, The Netherlands. The 
antibody preparation was diluted 1:5 to 1:10. 
(5) A rabbit antiserum to chicken gizzard desmin (pDes), 
prepared as described before (Ramaekers et al., 1983a). 
(6) A monoclonal antibody to chicken gizzard desmin (RD 
301), specific for desmin as demonstrated by immunoblotting 
and immunofluorescence assays (to be published). 
(7) A monoclonal neurofilament antiserum (MNF) reactive with 
the 70 kDa and 200 kDa neurofilament proteins. This 
antiserum can be purchased from Euro-Diagnostics B.V., 
Apeldoorn, or Sanbio B.V., Uden, The Netherlands. 
Corresponding fluorescein isothiocyanate- and Texas-red 
conjugated second antibodies were obtained from Nordic, 
Tilburg, The Netherlands, and from New England Nuclear, 
Boston, MA. 
In control experiments either second antibodies alone or 
primary antibodies to GFAP and a monoclonal antibody to 
epidermal keratin (RKSE 60 which reacts only with 
keratinizing epithelial cells) were used (Ramaekers et al., 
1983a). 
Gel electrophoresis and immunoblotting 
Cytoskeletal preparations from calf lens, bovine liver 
hepatocyte cultures and LLCMK-2 cultures were made by 
extracting cell pellets with 1% Triton X-100 in PBS, 
containing 0.01 mM phenylmethylsulfonyl fluoride (PMSF). 
The insoluble fraction was washed with PBS and applied to 
gel electrophoresis in sodium dodecylsulfate containing 10% 
Polyacrylamide slab gels as described by Laemmli (1970). 
Vimentin was purified from bovine lens as described before 
(Ramaekers et al., 1981). For immunoblotting experiments 
the electrophoretically separated polypeptides were 
transferred to nitrocellulose sheets using an 
electrophoresis buffer containing 25 mM Tris-HCl, 192 mM 
glycine and 20% methanol (pH 8.3), essentially as described 
by Towbin et al., (1979). The sheets were then exposed at 
room temperature and under constant shaking to the following 
incubation steps in sequence: preincubation for 3 h in 
buffer I, a 3% solution of bovine serum albumin (BSA from 
Sigma) in 350 mM NaCl, 10 mM Tris-HCl, pH 7.6, and 0.5 mM 
PMSF (Sigma); 3 washing steps for 10 min each in buffer II 
(0.5% Triton X-100 from BDH in PBS); incubation for 18 h 
with the first antibody in buffer III (0.3% BSA, 150 mM 
NaCl, 10 mM Tris-HCl, pH 7.6, 0.1 mM PMSF, 1% Triton X-100, 
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0.5% sodium deoxycholate from Merck, and 0.1% sodium 
dodecylsulfate (SDS from BDH). The vimentin monoclonal 
antibody was diluted 1:20; 3 washing steps, 10 min each in 
buffer III; 3 washing steps, 10 min each in buffer II; 
incubation for 60 min in peroxidase-conjugated rabbit 
anti-mouse IgG (Nordic, Tilburg, The Netherlands) diluted 
1:200 in buffer IV (0.5% Triton X-100, and 0.5% BSA in PBS); 
3 washing steps, 10 min each in buffer II. Peroxidase 
activity on the immunoblot was detected using 4-chloro-
1-naphtol from Merck (Darmstad, FRG). 50 mg of 4-chloro-
1-naphtol was dissolved in 5 ml ethanol, added to 95 ml PBS 
and stirred for 5 min. After filtration, 30% H202 was added 
to the solution to a final concentration of 0.06% (40 ul 30% 
H202 per 20 ml) and the peroxidase reaction developed by 
gentle shaking of the blot in this solution during 5 min. 
The sheets were then rinsed with tap water for 10 min and 
dried at room temperature between filter paper. 
RESULTS 
Antibodies 
The specificity and reactivity patterns of most of the 
antibodies used in this study have been described 
extensively before (Ramaekers et al., 1981, 1982, 1983a-e, 
1984a,b). In brief, the rabbit antiserum to callus keratins 
(pKer) reacted exclusively with most epithelial tissues, 
while the monoclonal antibody RGE 53 reacted with a subgroup 
of epithelial tissues, i.e. glandular and columnar 
epithelial cells and mesothelial cells. This antibody 
reacts specifically with cytokeratin 18 as detected by one-
and two-dimensional immunoblotting assays and does not seem 
to interact with other cytokeratin polypeptides or any of 
the other types of intermediate filament proteins. The 
rabbit antiserum to vimentin (pVim) was shown to react 
exclusively with the 57 kD vimentin protein in 
immunoblotting experiments (Herman et al., 1983). In 
general it is specific for cells of mesenchymal origin and 
does not react with epithelial cells in vivo (for exceptions 
see for example Herman et al., 1983). The commercially 
available monoclonal antibody to calf lens vimentin (MVI) 
was further characterized, using the indirect 
immunofluorescence technique on frozen sections and cell 
cultures as well as immunoblotting assays. It was obvious 
that the antibody reacted only with tissues of mesenchymal 
origin, such as fibroblasts, endothelial cells, some blood 
vessel smooth muscle cells (Fig. la), glomeruli in the 
kidney (Fig. lb) etc., but did not stain epithelial 
tissues. In cultured cells (bovine lens cells, BHK-cells, 
PtK-cells, HeLa cells, Kb cells and cultures from bovine 
hepatocytes) the antibody gave a filamentous staining 
pattern (Fig. 1c), identical to that obtained with the 
polyclonal antiserum to calf lens vimentin. Moreover, this 
antibody was tested on a series of frozen sections from 
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different types of human malignant tumors including 
astrocytomas, transitional cell carcinomas of the bladder, 
endometrial tumors, renal cell tumors, mesotheliomas, 
several other types of carcinomas and some sarcomas. From 
these experiments it was obvious that the monoclonal 
vimentin antibody gave a staining pattern virtually 
identical to that of the polyclonal vimentin antiserum 
(results not shown). In the immunoblotting technique (Fig. 
le) the antibody gave a specific positive reaction 
coinciding with the vimentin band seen at 57 kD in the 
Coomassie-stained gel strip or its replica. Cytoskeletal 
extracts from bovine lens and LLCMK-2 cell cultures next to 
purified bovine lens vimentin were used as antigen 
preparations. 
Table 1: Distribution of intermediate filament proteins IFF in different 
cell types of normal testis as detected with several IFP-antibodies 
, 
[Cell type 
ι _ _ _ _ 1 
|Spermatogonia 
ISertoli cells 
1 
|Leydig cells 
1 
|Myoid cells surrounding 
|seminoferous tubules 
1 
|Rete testis lining cells 
|Ductus efferens lining 
|cells 
1 
INerve cells 
pKer 
-
-
-
+ 
+ 
_ 
RGE 53 
-
-
-
+ 
N.T./a 
_ 
pVim 
-
+ 
+/-
+/-
+ 
-
_ 
М І 
-
+ 
+/-
+/-
+ 
N.T. 
_ 
pDes 
-
-
-
+ 
-
-
_ 
RD301 
-
-
-
+ 
-
N.T. 
_ 
| 
MNF 
-
-
-
-
-
-
+ 
a) N.T.: not tested. 
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Table 2: Climcopathological data and immunohistochemical detection of 
intermediate filament proteins (IFP) in human testicular germ cell tumors 
| 
Pat. 
Age 
| 1-39 
| 2-26 
| 3-4Θ 
| 4-27 
| 5-39 
| 6-50 
| 7-32 
| 8-40 
| 9-34 
110-19 
111-20 
112-29 
113-26 
Tumor location 
and diagnosis 
Anaplastic 
seminoma testis 
Anaplastic semi 
noma mediast. 
Seminoma 
testis 
Seminoma 
testis 
Seminoma 
testis 
Seminoma 
testis 
Lymph node 
metast. anapl. 
seminoma 
Embryonal cell 
testis care. 
Embryonal cell 
care./seminoma 
in the testis 
Endoderm, sinus 
tumor/local 
recurr. scrotum 
Endoderm, sinus 
tumor metast. 
on the omentum 
Embrional cell 
care.Lymph node 
metast./chorio 
care, component 
Teratocarcinoma 
testis: 
glandular comp. 
squamous comp. 
spindle cell 
loose disp. eel 
Stage 
PT2/3 
N0M0/A 
TXNXMX 
/c 
pTl 
N4M1/C 
pTl 
N0M0/A 
pTl 
N2M0/B 
pTl 
NOMO/A 
pTl 
N4M1/C 
pTl 
NOMO/A 
pTl 
N1M0/B 
pT4 
N2M0/B 
pT4 
N2MO/B 
pTl 
N2M0/B 
pTl 
N2M0/B 
Follow 
up 
Yrs 
3.7 
1.3 
0.3 
0.3 
0.3 
0.5 
1.5 
2.0 
0.3 
2.4 
2.4 
1.3 
1.5 
Clinical 
status/a 
A 
D 
D 
A 
A 
A 
A 
A 
A 
D 
D 
A 
A 
Levels of 
FP/a and/ 
or HCG/a 
normal 
normal 
elevated 
normal 
normal 
normal 
normal 
elevated 
normal 
elevated 
elevated 
elevated 
elevated 
Reactivity | 
of IFP antisera in 
the tumor cells 
pKer 
-/b 
— 
+/-
/b 
-/b 
-/b 
-/b 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+/e 
+ 
RGE53|pVim 
-/b 
— 
+/-
/b 
-/ь 
-/b 
-/b 
+ 
+ 
+ 
+ 
+ 
+ 
-
+/e 
+/C 
+/C 
+/c 
+/c 
+/C 
+ 
+/C 
_ 
-/d 
-
-
+/e 
И І | 
+/c| 
+/c| 
+/c| 
+ | 
-/d 
1 
-
-
+/e| 
1 
(a) Abbreviations: A: alive; D: dead; FP: Alpha foetoprotein; HCG: Beta 
human chorionic gonadotropin. (b) Occasionally a few cytokeratin positive 
cells were seen . It has not been possible so far to determine whether these 
cells were malignant or whether they represented preexisting epithelial cells. 
In case nr.3, however, it was quite obvious that also tumour cells contained 
cytokeratins. In case nr.7 the primary tumour in the testis contained a 
Yolk-sac component, as detected in H/E stained paraffin sections. 
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Figure 1 (a-e) Specificy test of the monoclonal antibody to 
vimentin (MVI). (a, b) Staining pattern on human kidney 
frozen sections showing a positive reaction in endothelial 
cells, bloodvessel smooth muscle cells, stromal cells and 
glomeruli, but no reaction in epithelial cells. (c, d) 
Bovine cultured lens cells showing a fibrillar staining 
pattern after incubation with the MVI antibody (c) but not 
with the FITC-conjugated goat-anti-mouse antibody alone (d). 
(e) Immunoblotting of MVI on a cytoskeletal preparation from 
LLCMK-2 cells (lane 1), bovine lens (line 2) and on purified 
bovine lens vimentin (lane 3). Note only a strong reaction 
with vimentin (V). Bars indicate 50 um. 
Table 2: (c) Also (considerable amounts of) vimentin 
negative tumour cells were seen. (d) Only a few vimentin 
positive cells were found. (e) Some of the cells in the 
spindle cell component seem to co-express cytokeratin and 
vimentin as detected by double label immunofluorescence (see 
text). Case 10 and 11 represent the same patient. 
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intermediate filament pattern in normal human testis 
When normal human testes, either as frozen sections or 
as paraffin sections were incubated with the antiserum 
described above and in the Materials and Methods section, 
the following distribution of IFF was observed (see also 
Table 1). With the cytokeratin antibodies pKer and RGE53 a 
strongly positive reaction was seen only in the epithelial 
cells lining the ductus efferens and the rete testis (Fig. 
2a, b). No other cell types were positive. The antibodies 
to vimentin did not stain the epithelial cells of the ductus 
efferens (Fig. 2c). Strikingly, however, a considerable 
part of the epithelial cells of the rete testis were also 
positive for vimentin (Fig. 2d). Double-label experiments, 
using pKer and MVI or pVim and RGE 53 as primary antibody 
mixtures, clearly demonstrated this co-expression of 
cytokeratin and vimentin in rete testis lining epithelial 
cells (Fig. 2g, h). Furthermore, a positive reaction with 
the vimentin antibodies was found in Sertoli cells and in 
Leydig cells (Fig. 2f). The latter cells, however, showed 
a variable reaction, with some Leydig cells negative and 
others containing perinuclear clusters. Fibroblasts and 
blood vessels were also stained (Fig. 2c, d, f). Myoid 
cells surrounding the seminiferous tubules were strongly 
positive with the antibodies to desmin (Fig. 2i). Some of 
these myoid cells could be shown to co-express desmin and 
vimentin as demonstrated in the double-label indirect 
immunofluorescence technique using pDes and MVI or pVim and 
RD 301 as primary antibody mixtures (Fig. 2i, j). 
Figure 2 Immunoperoxidase (a-f) and double-label indirect 
immunofluorescence (g-j) staining of normal human testis 
tissues with the antibodies to cytokeratin (a, b, g), 
vimentin (с, d, f, h, j) and desmin (e, i) showing the 
ductus efferens (a, c, e), the rete testis (b, d, g, h) and 
seminiferous tubules (f, i, j). Bars indicate 50 um. 
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The desmin antibodies did not stain any other cell types 
than muscle cells (see also Fig. 2e). The neurofilament 
antibody only stained nerve cells. 
Testicular tumors 
The staining patterns obtained with the cytokeratin and 
vimentin antibodies in the different testicular germ cell 
tumors are summarized in table 2 and depicted in Figs. 3-5. 
Seminomas 
Four classic seminomas, an anaplastic seminoma in the 
testis and two metastases of anaplastic seminomas were 
examined for their IFP-content using the antibodies to 
vimentin and cytokeratin. It was obvious that in all cases 
tumor cells were positive for vimentin as detected by the 
polyclonal antiserum (Fig. 3a) but also a considerable 
number of vimentin negative tumor cells were seen. Four 
cases were examined with the monoclonal anti-vimentin 
antibody, which gave results similar to those obtained with 
the polyclonal antiserum. Again vimentin-negative tumor 
cells were seen. The vimentin antibody also stained stromal 
components (fibroblasts, blood vessels) and Sertoli cells. 
When incubated with the polyclonal or monoclonal antibodies 
to (cyto)keratins six out of seven cases were negative (Fig. 
3b) although in four of these cases a few cytokeratin 
positive cells scattered through the tissue sections were 
seen. It was not possible to determine whether these latter 
cells were malignant tumor cells or if they represented 
preexisting epithelial cells from, for example, the rete 
testis. 
In case no. 7, a lymph node metastasis which was 
morphologically pure anaplastic seminoma, a few cytokeratin 
positive cells were detected.This correlates well with the 
finding that the primary tumor in the testis was a mixed 
Yolk-sac tumor/seminoma. From earlier studies (Ramaekers et 
al., 1983d) we know that this latter type of germ cell tumor 
is positive for cytokeratin but negative for vimentin. 
Double labeling studies performed on frozen sections from 
case no. 7 supported this suggestion. A complete overlap 
of the reaction pattern of the polyclonal and the monoclonal 
anti-cytokeratin antibodies was seen with the reaction of 
the monoclonal antibody stronger than that of the polyclonal 
antiserum. No overlap was observed between the reactivity 
patterns of the polyclonal vimentin antiserum and RGE 53. 
We have, however, also observed tumor cells that were 
negative for both cytokeratin and vimentin antibodies. 
Interestingly, in one of the cases (no. 3 which had 
elevated levels of serum markers) it was quite obvious that 
tumor cells were also positive for cytokeratin (Fig. 3c). 
Double-label studies in this case again showed a total 
overlap between reactivity patterns of the two cytokeratin 
antibodies, the monoclonal antibody reacting more strongly 
than the rabbit antiserum. No overlap was seen in the 
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reactivity patterns of the polyclonal vimentin antiserum and 
RGE 53 on one hand or between the monoclonal vimentin 
antibody and the polyclonal keratin antiserum on the other 
hand (Fig. 3c, d). Furthermore, it was clear that tumor 
cells staining neither for cytokeratin nor vimentin were 
also present in this case. In no case of seminoma was a 
positive reaction found in the tumor cells with antibodies 
to desmin, GFAP or the monoclonal antibodies RKSE 60 or MNF. 
The desmin antibodies did, however, stain preexisting and 
vascular smooth muscle tissues, while MNF stained nerve 
cells. 
Figure 3 (a-d) Seminoma frozen sections, incubated with the 
polyclonal antibody to vimentin (a, b, e), the polyclonal 
antibody to cytokeratins (c) and RGE 53 (d). d and e 
represent double-label immunofluorographs of case nr. 3 in 
an area with a high concentration of cytokeratin-positive 
cells. Bars indicate 50 um. 
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Non-seminomatous testicular tumors 
Five non-seminomatous testicular tumor cases, including 
two primary and one metastatic embryonal cell carcinoma, one 
primary and one metastatic endodermal sinus tumor and a 
teratocarcinoma, were tested for their IFP-type. The two 
samples of the endodermal sinus tumor (cases 10 and 11) were 
from the same patient, obtained about one year apart. 
When incubated with the different types of antibodies the 
tumor cells in all five embryonal cell tumors reacted only 
with the polyclonal and monoclonal (cyto)keratin antibodies 
(Fig. 4a, c, d) but not with the polyclonal or monoclonal 
vimentin antiserum (Fig. 4b). The reaction of RGE 53 was 
normally slightly more intens than the reaction with the 
rabbit anti-keratin antiserum pKer (compare figures 4a and 
4d). Stromal components of the tumor were positive for 
vimentin only. When double-label immunofluorescence 
microscopy was applied to cases nr. θ and 9 using the 
rabbit antiserum to vimentin in combination with RGE 53 or 
the monoclonal antibody to vimentin in combination with the 
polyclonal anti-cytokeratin antiserum, it was obvious that 
both reactions are mutually exclusive (Fig. 4e, f). No 
reaction was found in the tumor cells with the antibodies to 
desmin, GFAP, MNF, or with RKSE 60. 
The teratocarcinoma in the left testis (case 13) could be 
shown to contain different types of epithelial 
differentiations in H&E stained sections. In addition to 
keratinizing stratified squamous epithelium and ducts 
consisting of columnar and mucus producing epithelium, an 
additional component consisting of more atypical cells, 
focally forming ducts, and focally growing as solid nests, 
was observed. The stroma had a myxoid appearance. When 
frozen sections of this tumor were incubated with the rabbit 
antiserum to keratin, virtually all tumor cells, including 
the glandular-, squamous-, and spindle cell components as 
well as most dispersed tumor cells, were positive (Fig 5a, 
c, e). When incubated with RGE 53 a distinction could be 
made between the glandular component of the tumor (which was 
RGE 53 positive) and the squamous component (which was 
negative for RGE 53; compare Figs. 5c-f). Surprisingly, 
like all other components of the tumor, this latter 
component was negative with RKSE 60, the monoclonal antibody 
specific for keratinizing cells. 
When incubated with the antibodies to vimentin, only the 
spindle cell component was stained in addition to (other) 
stromal elements (Fig. 5b). Double label 
immunofluorescence studies revealed a complete overlap 
between the staining patterns of the antikeratin rabbit 
antiserum and RGE 53 in the glandular component of the tumor 
and no overlap in the squamous component (Fig. 5c-f). An 
overlap between the staining patterns of the polyclonal 
antiserum to vimentin and RGE 53 on one hand or the 
polyclonal antiserum to keratin and the monoclonal antibody 
to vimentin on the other hand, was seen only in some spindle 
cells but not in other components of the tumor or stroma 
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(Fig. 5g-j). Although not generally observed, 
co-expression of cytokeratins and vimentin has also be 
detected in some other types of tumor cells (see for example 
Herman et al., 1983 and Ramaekers et al., 1983e). No 
reaction was seen in this tumor with the antisera to desmin, 
GFAP, or neurofilaments. 
Figure 4 (a-f) Embryonal cell carcinoma frozen sections, 
incubated with the polyclonal antibody to cytokeratins (a), 
the polyclonal antibody to vimentin (b, f) and RGE 53 (c, d, 
e). e and f represent double-label immunofluorographs. 
Bars indicate 50 um. 
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Figure 5 (a-f) Double-label indirect immunofluorescence 
staining patterns of the teratocarcinoma, incubated with the 
cytokeratin antibodies (a, c, e, pKer; d, f, g, i, RGE 53) 
and the vimentin antibody (b, h, j). Bars indicate 50 um. 
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In the practical management of malignant germ cell 
tumors of the testis, the most important diagnostic 
distinction is between seminomas on the one hand and 
non-seminomatous tumors including embryonal carcinoma, 
endodermal sinus tumor, teratocarcinoma and choriocarcinoma 
on the other hand (Paulson et al., 1982; Mostofi, 1973). In 
practice the only situation in which real diagnostic 
difficulties may be encountered is the distinction between 
anaplastic seminomas and embryonal cell carcinomas. This 
distinction is an important one, however, since these tumors 
show significant differences in sensitivity to irradiation 
and in prognosis. Therefore, proper diagnosis of these germ 
cell tumors is essential for the selection of treatment 
modalities. 
In some of these tumors an overlapping of diagnostic 
criteria such as cell and nuclear size, pleomorphism, and 
arrangement as well as presence of a lymphocytic infiltrate 
may cause confusion. The results described here with 
intermediate filament protein antibodies show that seminomas 
contain mainly vimentin as their intermediate filament 
protein. In contrast, embryonal cell carcinomas usually 
contain cytokeratin but not vimentin. 
Some tumors which are histologically classified as seminomas 
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may show elevated serum levels of beta-HCG and/or alpha-FP. 
It has been proposed that these seminomas have a 
significantly worse prognosis than those with normal serum 
levels of these markers (Morgan et al., 1982). However this 
interpretation remains controversial (Mauch et al., 1979). 
It is of interest that the one patient in our series who 
presented with a histologically pure seminoma but elevated 
serum levels of beta-HCG and alpha-FP also showed an 
intermediate filament protein pattern intermediate between 
seminoma and embryonal cell carcinoma (see Table 2). 
However it is important to note that a mixed embryonal cell 
carcinoma/seminoma is characterized and recognized as such 
(because of extensive cytokeratin positive tumor areas) 
although the serum markers were not elevated. 
Based on these studies and those previously reported 
(Battifora et al., 1984) we conclude that intermediate 
filament typing of testis tumors may provide a useful 
adjunct to routine histology and determination of serum 
beta-HCG and alpha-FP in determining therapy and prognosis. 
The routine use of antibodies to vimentin in addition to 
cytokeratins provides a useful positive test to corroborate 
the cytokeratin negativity of seminoma. 
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CHAPTER IV 
APPLICATION OF ANTIBODIES TO INTERMEDIATE FILAMENT 
PROTEINS AS TISSUE SPECIFIC PROBES IN THE FLOW 
CYTOMETRIC ANALYSIS OF COMPLEX TUMORS 
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ABSTRACT 
The flow cytometric analysis of carcinomas is often 
hampered by the presence of stromal and inflammatory cells 
in the cell suspensions obtained from such neoplasms. 
Therefore, a flow-cytometric method was developed to 
distinguish epithelial from non-epithelial cells using 
polyclonal and monoclonal antibodies to (cytojkeratins, the 
epithelial type of intermediate filament proteins. 
Using a model system of cultured bladder carcinoma (T24) and 
leukemia (MOLT-4) cells, we have tested our hypothesis and 
procedures by labelling cell mixtures with these antibodies. 
After incubation with an appropriate intermediate filament 
antibody and propidium iodide staining the DNA content and 
distribution of T24 cells could be analysed separately from 
MOLT-4 cells. 
When applied to cell suspensions of endometrial carcinomas, 
bladder carcinomas and Grawitz tumors only the epithelial 
primarily carcinoma cells were stained for cytokeratin and 
these cells could thus be analysed separately from stromal, 
inflammatory and other non-epithelial cells. 
In this way, a more accurate flow cytometric analysis of the 
malignant fraction within a tumor can be achieved. 
INTRODUCTION 
All eukaryotic cells contain an intracellular network 
of protein filaments with varying diameters, the so called 
cytoskeleton. In addition to microfilaments and 
microtubules, a class of 7-11 nm filaments can be 
recognized. These intermediate-sized filaments, which 
comprise a considerable part of the water insoluble 
cytoskeleton, have been elaborately described (4) and are 
known to be tissue specific (12). 
Recent investigations have shown that all types of 
epithelial cells contain cytokeratins (23), while 
mesenchymal cells contain vimentin as their intermediate 
filament protein. Muscle cells contain desmin IF, while 
neural tissues contain glial fibrillary acidic protein 
(GFAP) or neurofilaments. 
Antibodies to these different types of intermediate filament 
proteins (IFF) can be used in the immunohistochemical 
characterization of normal tissues, cell cultures, and 
benign and malignant tumors (13, 18). For example, 
carcinomas normally contain only cytokeratins, while 
malignant lymphomas contain only vimentin IF (18). 
Moreover, since cytokeratins consist of a number of 
biochemically and immunologically different proteins, which 
occur in tissue specific combinations (11), monoclonal 
antibodies to these different cytokeratin types allow the 
distinction between different kinds of epithelial cells (3, 
10, 25). For example, monoclonal antibodies to cytokeratin 
18 have been prepared that are able to distinguish squamous 
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epithelium (cytokeratin 18 negative) from glandular and 
columnar epithelium which contains cytokeratin 18 (3, 17). 
It is obvious that such tissue markers are valuable tools, 
not only in the immunohistological classification of normal 
and malignant tissues (13, 18), but also in cytology (20) 
and cytometry. Flow cytometric analysis of cell suspensions 
has proven to be useful as a technique for the estimation 
and quantitation of several cellular components. Special 
attention has been focussed on the measurement of DNA 
content in cells, which may be used to estimate ploidy and 
proliferative capacity of tumors (8, 9). However, analysis 
of mixed cell populations, which are normally obtained from 
tumors, gives rise to data which are sometimes difficult to 
interpret. The tumor cell suspensions usually contain 
variable amounts of other cell types, such as inflammatory 
and stromal cells. 
We have developed a flow-cytometric procedure to distinguish 
epithelial, primarily tumor cells from non-epithelial cells 
in such mixed cell populations on basis of their 
intermediate filament type. With this method it is possible 
to analyse simultaneously the DNA content distribution of 
the two cell populations. In this article we review our 
earlier published findings with a model system of mixed 
cultured cells, in which we have tested our hypothesis (21, 
22). Furthermore, our observations with cell suspensions 
obtained from gynecological (14) and urological tumors are 
briefly summarized. 
MATERIALS AND METHODS 
Cells and tissues 
T24 cells are derived from a human transitional cell 
carcinoma. These cells grow in tissue culture and are 
positive for cytokeratin when tested in the indirect 
immunofluorescence technique. MOLT-4 cells are a culture of 
T-cells derived from a patient with acute lymphatic 
leukemia. These cells are negative for cytokeratin. Cells 
attached to the bottom of the tissue culture flask were 
covered with a minimal amount of 0.25% trypsin in PBS or 
culturing medium without calf serum. After 5-10 minutes at 
37C the cells were suspended in PBS and centrifugea for 5 
min at 400 χ g. The supernatant was discarded but fluid 
sticking to the wall of the tubes was allowed to cover the 
pellet. Then the pellet is vortexed vigorously and the 
cells are suspended in this small volume of PBS. Then 70% 
ethanol (-20C) was added rapidly under constant vortexing or 
shaking. The final concentration in our experiments was 
about 3 χ 10e6 cells/ml ethanol. At this stage the cells 
could be stored at -20C. 
Liquid nitrogen stored material from normal human 
endometrium and endometrial carcinomas was homogenized in 
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PBS using a Dounce homogenizer (loose fitting pestle). 
Preparation of single cell suspensions and fixation was 
performed as described elsewhere (14). Transitional cell 
carcinomas of the bladder and renal cell tumors were brought 
into cell suspensions using enzymatic digestion (collagenase 
+ DNAse) as described in detail before (6). Fixation of 
these cell suspensions in 70% ethanol is as described above 
for cultured cells. 
Antibodies 
Antibodies used in our study are: (1) RGE 53, a 
monoclonal antibody to cytokeratin 1Θ, one of 19 
cytokeratins present in human epithelial tissues. This 
antibody is specific for glandular epithelia and does not 
react with squamous epithelia (17). Undiluted culturing 
supernatant was used for labelling of cell suspensions. (2) 
An affinity purified polyclonal rabbit antiserum to human 
skin keratins which reacts with virtually all epithelial 
tissues, but not with non-epithelial tissues (16). The 
antiserum was diluted 1:5 in PBS. (3) A rabbit antiserum 
directed against calf lens vimentin, which reacts with cells 
of mesenchymal origin but normally does not stain epithelial 
cells (15). This antiserum was diluted 1:20 in PBS for our 
tests. 
Labelling of the cell suspensions 
The immunocytochemical staining procedure was performed 
at room temperature. The endometrial cell suspensions were 
labelled as described before (14). 
Fixed suspensions from cultured cells, bladder carcinomas 
and renal cell tumors were split into three fractions. One 
sample was stained with PI as described below and used for 
cell kinetic studies. A second sample was used for 
estimation of the DNA-index, with chicken red blood cells as 
internal standard (5, 24). The third sample was labelled as 
follows. 
About 1 χ 10E6 cells in ethanol (-20C) were centrifuged at 
room temperature (15 min, 400 χ g) and the pellet washed 
with 1 ml of 5% Fetal Calf Serum (FCS; Gibco Europe B.V., 
The Netherlands) in buffer A (B.01 g NaCl, 0.2 g KCl, 1.44 g 
Na2HP04, 0.2 g KH2P04 in 1000 ml distilled water, pH 7.4) 
and pelleted again. 
The pellet was resuspended in 0.2 ml of antiserum, either as 
culturing supernatant or diluted in 5% FCS in buffer A, and 
incubated 30 min at room temperature under regular shaking. 
Then the cells were washed three times in 1.0 ml buffer A 
containing 5% FCS. 
After the last washing step the cell pellet was resuspended 
in 0.5 ml of FITC-conjugated second antibody, diluted 1:25 
in buffer A containing 5% FCS. As second antibodies either 
FlTC-goat-anti-rabbit IgG or rabbit-anti-mouse IgG (Nordic, 
Tilburg, The Netherlands) were used. After incubation for 
30 min at room temperature under regular shaking the cells 
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were washed as described above. The cell pellet was 
resuspended in 1 ml of a propidium iodide solution (20 mg/1 
A-grade in 150 mM sodium phosphate buffer pH 7.4; 
Calbiochem, Boehring Corp., La Jolla, CA, USA). 
To 1 ml of this cell suspension, 0.1 ml of a stock-solution 
of RNA-ase (1% type A in sodium phosphate buffer; Sigma, St. 
Louis, MO, USA) was added and the suspension was incubated 
for exactly 10 min at 37C. Then the cell suspension was 
filtered through a 100 micron nylon filter (Ortho 
Diagnostics Systems, Beerse, Belgium). Cells were kept in 
the dark at room temperature prior to FCM-analysis. 
FCM analysis 
Cell analysis and sorting was performed using a 
cytofluorograph system 50H (Ortho Instruments, Westwood, MA, 
USA). Fluorochromes PI and FITC were excited by a 4ΘΘ nm 
wavelength light beam from an argon ion laser (Spectra 
Physics, Mountain View, CA, USA). Fluorescence was measured 
simultaneously using a 515-530 nm filter and a longpass 630 
nm filter for FITC and PI, respectively. A two color 
compensation network has been used to compensate for color 
overlap between green and red fluorescence, using a single 
stained fraction as reference. 
All data were stored in correlated (list) mode on a PDP 
11/34 computer (Digital Equipment Corporation, Maynard, MA, 
USA) for subsequent data analysis. 
The normal human Gl DNA index in our laboratory is 2.65 to 
2.75 times the fluorescence intensity of chicken 
erythrocytes. 
RESULTS 
When frozen sections of normal human tissues and tumors 
are incubated with antibodies to cytokeratins, only 
epithelial cells, benign and malignant, are stained positive 
in the indirect immunofluorescence technique (13, 15, 18). 
For example, transitional cell carcinomas of the bladder are 
positive for cytokeratin (Fig. la). The same is true for 
endometrial carcinoma (Fig. lb). Furthermore, when applied 
to cells in tissue culture, again only cells of epithelial 
origin seem to contain cytokeratins (4, 12). For example, 
when applied to T24 bladder carcinoma cells grown on a 
coverslip, cytokeratin antibodies detect an intracellular 
filamentous network, in cells fixed in methanol and acetone 
(Fig. 2). Molt-4 leukemia cells do not stain with the 
cytokeratin antibodies. An antibody to vimentin, the 
mesenchymal type of IFP, does not normally stain epithelial 
cells in situ. In general, fibroblasts, blood cells and 
inflammatory cells, blood vessel endothelium and some 
vascular smooth muscle cells are positive for vimentin (Fig. 
1c). Solid carcinomas do not normally stain for vimentin 
Page 73 
(Fig. le). One exception to this rule, however, is 
represented by renal cell adenocarcinoma. The malignant 
cells of this type of neoplasm can co-express cytokeratins 
and vimentin (7) (Fig. 3). 
in order to show that antibodies to cytokeratins can be used 
to analyse epithelial fractions of mixed cell populations 
and to test our hypothesis and methods we have first applied 
the staining procedure to a model system of mixtures of 
established tumor cell lines (Fig. 4). 
Mixtures of ethanol-fixed epithelial T24 bladder carcinoma 
cells and non-epithelial Molt-4 leukemia cells were labelled 
with a cytokeratin antibody and thereafter with an 
appropriate FlTC-conjugated second antibody. After 
propidium iodide (PI) staining and subsequent 
flow-cytometric analysis for FITC and PI intensitiy, it was 
obvious that only the epithelial T24 cells were stained for 
cytokeratin. 
Analysis of pure T24 cells shows a single population of 
cells with a DNA index of 1.56 and all cells staining for 
cytokeratins. Molt-4 cells show a higher DNA index of 2.03 
and no reaction with the antibodies. Mixtures of T24 and 
Molt-4 cells can be separated into the individual cell 
populations on basis of cytokeratin staining of the T24 
cells. DNA histograms of the two different cell types can 
be obtained by interactively placing a window in the 
two-dimensional histogram (Figure 4). Comparison of these 
data with those of the pure cell cultures, analysed for DNA 
content and distribution before mixing, revealed identical 
histograms. 
Table I: Cell cycle analyses of T24- and Molt 
4-cells in pure populations (P) and 
after FCM of the mixture (M). 
T24 
Gl 
S 
G2M 
Ρ 
7 2 . 7 
1 9 . 4 
7 . 8 
% 
% 
% 
M 
7 3 . 4 % 
1 8 . 6 % 
8.0 % 
M o l t - 4 
Gl 
S 
G2M 
5 6 . 2 
3 4 . 0 
9 . 8 
% 
% 
% 
5 6 . 0 % 
3 4 . 6 % 
9 . 4 % 
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Figure 1 Immunofluorescence micrographs of (a, c) bladder 
carcinomas and b) a moderately-well differentiated 
endometrial carcinoma, stained for cytokeratin with a rabbit 
antiserum to skin keratin (a, b) or for vimentin (с) with a 
rabbit antiserum to calf lens vimentin (a xlOO; b χ 250; с 
xlOO). Note that epithelial tumor cells are stained for 
cytokeratin only while stromal components are only stained 
for vimentin. 
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Figure 2 Immunocytochemical demonstration of cytokeratin 
intermediate filaments in cultured T24 bladder carcinoma 
cells using a monoclonal antibody to cytokeratin 18 (RGE53). 
Figure 3 Immunofluorescence micrographs of a renal cell 
tumor (Grawitz tumor) illustrating co-expression of 
cytokeratin and vimentin in the tumor cells. 
(a) Cytokeratin as detected by the polyclonal antibody. 
Stromal cells are negative. 
(b) Vimentin as detected by the polyclonal antiserum to calf 
lens vimentin. Note the positive reaction in both tumor 
cells and stroma cells (a x400; b x400). 
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Figure 4 Three-dimensional (A) 
projection of DNA content 
and two-dimensional (В) 
(as PI fluorescence) and 
cytokeratin content (as FITC fluorescence) in cells of a 
mixture of T24 and Molt-4 cells. The indicated square in A 
shows the window used for a separate analysis of cytokeratin 
positive T24 cells (A) and cytokeratin negative Molt-4 cells 
(B). 
Figure 5 FCM analysis of cells from a well differentiated 
endometrial adenocarcinoma (A) stained with PI for cellular 
nucleic acid (ordinate) and with RGE53 and FITC for 
cytokeratin (abscissa). Limits of PI and FITC positive 
populations are indicated by the sorting window (B). 
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Figure б FCM-analysis of a transitional bladder cell 
carcinoma in suspension after labelling for cytokeratin 
using the polyclonal keratin antiserum (FITC-channel) and 
staining with PI. 
A) Two parameter (FITC for cytokeratin and PI for DNA) 
analysis showing position of the window containing 
epithelial cytokeratin positive cells. The cytokeratin 
negative, aneuploid fraction is represented by naked nuclei, 
as judged from microscopical observations. 
B) DNA histogram of the total cell suspension. 
C) DNA histogram of cytokeratin positive cells selected by 
placing a window as illustrated in A. D) DNA histogram of 
cytokeratin negative cells. 
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The distribution of cells in the different phases of the 
cell cycle in the two cell populations agrees with the data 
derived from the pure populations (Table I). 
Encouraged by these data we have applied the method to cell 
suspensions from solid normal tissues and tumors, which are 
always mixtures of different cell types. 
When cells isolated from the endometrium and stained for 
cytokeratin and DNA were analysed by flow cytometry, several 
cell populations could be distinguished. Cells positive for 
cytokeratin can be distinguished clearly from negative 
cells. Furthermore PI staining distinguishes cells 
containing nuclei from cell debris and loose cytoplasmic 
fragments. A DNA histogram of the cytokeratin positive 
cells can readily be obtained from these data. In this 
material the position of the endometrial cell GO/Gl peak was 
2.7 times that of chicken erythrocytes, a normal human 
diploid ratio. 
Similar studies were performed with neoplastic lesions of 
the endometrium. Figure 5a shows a three-dimensional 
histogram of cells from a well differentiated adenocarcinoma 
of the endometrium including chicken erythrocytes as an 
internal standard. Again epithelial cells (RGE53 positive) 
can be clearly distinguished. In the sample illustrated, 
the main fraction of the adenocarcinoma cells is found in 
the diploid region. When a window is placed interactively 
in this histogram (Fig. 5b), RGE 53 positive nucleated 
cells can be separated from RGE 53 negative objects and cell 
debris. 
The correctness of the window was checked by sorting samples 
of cells on glass slides, by examination of these 
preparations in the fluorescence microscope and after 
routine cytological staining. In these sorted samples, only 
cytokeratin- and Pl-positive cells were found in contrast to 
unsorted cell suspensions. Furthermore, cell morphology was 
well preserved and indicated the presence of mainly (if not 
only) epithelial tumor cells (14). 
When ethanol fixed cell suspensions from bladder 
transitional cell carcinomas were incubated with the 
polyclonal cytokeratin antibody and thereafter with an 
appropriate FITC-conjugated second antibody and PI, again 
the carcinoma cells could be separated from stromal and 
inflammatory cells (Fig. 6). However, as can be judged 
from figures 6a and 6d, a cytokeratin negative, aneuploid 
fraction is often present in these cell suspensions. We 
have sorted this population and after microscopical 
inspection we could conclude that it represents naked 
nuclei, which always occur in enzymatically or mechanically 
obtained cell suspensions from solid tumors. After 
comparing several DNA-profiles of labelled and unlabelled 
cells, we further conclude that this phenomenon has no 
significant impact on the DNA distribution histograms of a 
tumor. 
Analysis of the cytokeratin and PI positive bladder cells 
revealed tumor cells ranging in DNA index from 0.94 to 2.02 
(normal human diploid equals 1.0). 
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In addition, fig. 7 shows a cell suspension from a bladder 
carcinoma in which very few tumor cells are recognized by 
one-dimensional DNA FCM (Fig. 7a). In contrast, 
double-labelling (Fig. 7b) allows the cytokeratin positive, 
aneuploid tumor cells to be distinguished clearly from the 
stromal cells and also from the cytokeratin positive but 
diploid bladder epithelial cells. 
When fixed cell suspensions from renal cell tumors were 
incubated with the monoclonal or polyclonal antibodies to 
cytokeratins and thereafter with an appropriate 
FITC-conjugated second antibody and PI the epithelial 
component of this tumor could be distinguished from other, 
non-epithelial, cell types (Fig. 8a). Also in cases where 
only small numbers of epithelial tumor cells were present in 
the cell suspensions aneuploid cells could be detected by 
the application of the cytokeratin staining procedure. In 
some cases labelling of the cells with the antiserum to 
vimentin revealed a FITC positive aneuploid subpopulation of 
cells in addition to diploid renal cells, stromal and 
inflammatory components (Fig. 8b). 
Figure 7 FCM of a transitional cell carcinoma in suspension. 
Note tHat the small fraction of aneuploid tumor cells 
(indicated by an arrow in A and B), hardly recognized by 
one-dimensional DNA FCM (A) is very well distinguished from 
non-tumor cells after double-labelling with PI and FITC for 
cytokeratin (B). 
В 
PI 4c Í 
JlBB l i s · zee 
ж 
гсі^" 
FITC 
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Figure 8 Two parameter (FITC for cytokeratin or vimentin and 
PI for DNA) analysis of renal cell tumor suspensions 
incubated with the monoclonal antibody to cytokeratin 18 
(RGE53) (A) or incubated with the polyclonal antiserum to 
vimentin (В). Note that the aneuploid tumor cells (arrows) 
can be positive for both cytokeratin and vimentin. A and В 
represent profiles of two different tumors, at different 
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Therefore these antibodies are already widely used as tissue 
markers for histopathology and cytopathology (13, 18, 20). 
Flow cytometric analysis of mixed cell populations such as 
are obtained from tumors produces results which are often 
difficult to interpret because of the variable mixture of 
cells of interest, usually carcinoma cells, with other cells 
such as inflammatory and stromal cells. In some material 
these cell populations can be discriminated, while most 
tumor material continues to be difficult to analyse and 
interpret (1, 2, 8, 9). 
Because of the ubiquitous presence of cell type specific 
intermediate filaments, immunofluorescence of these 
structures can be used for FCM analysis of many solid 
tumors. All carcinomas can be distinguished from 
non-epithelial cells by broad-spectrum cytokeratin 
antibodies and adenocarcinoma cells from non-glandular 
epithelium and non-epithelial elements by antibodies 
specific for glandular cells (17). In addition, antibodies 
specific for muscle cells (anti-desmin), neural cells 
(anti-neurofilament) and glial cells (anti-glial fibrillary 
acidic protein, GFAP) are available (18) and the tumors 
derived from these cell types can thus be specifically 
distinguished by use of the appropriate antibody. In flow 
cytometry (FCM) these tissue specific markers allow 
recognition, analysis and sorting of the specific cell types 
of interest excluding stromal and inflammatory elements. 
Two advantages of the application of cytokeratin antibodies 
in such FCM selection procedures have become obvious in the 
present experiments. 
First, in those cases of carcinomas where an aneuploid tumor 
cell peak could be detected in the one-dimensional 
DNA-profile, labelling of the epithelial tumor cells with 
FITC for cytokeratin allowed the analysis of the DNA 
distribution in the tumor and estimation of its 
proliferative fraction S-phase separately from the stromal 
and inflammatory components. 
Second, in those tumorfTactions where the malignant cells 
represent only a small fraction of the cells in suspension, 
and thus can not be recognized in the one-parameter 
analysis, labelling of the cells in suspension clearly 
displays such minor fractions in a two-parameter analysis, 
allowing the estimation of their ploidy and proliferative 
fractions. It should also be stated here that for 
succesfull labelling studies it is essential to have good 
quality cell suspensions. 
In summary we conclude that antibodies to intracellular 
intermediate filament proteins, especially the cytokeratins, 
can succesfully be applied for the flow cytometric analysis 
of most carcinomas in dealing with the common problem of 
stromal and inflammatory cell admixture. 
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ABSTRACT 
Thirty eight transitional cell carcinomas (TCC) were 
analysed by flow cytometry (FCM) using propidium iodide for 
DNA analysis and antibodies to cytokeratin by indirect 
immunofluorescence. By means of two-dimensional FCM 
analysis, cytokeratin-positive tumor cells could be analysed 
separately from cytokeratin-negative stromal and 
inflammatory cells. This resulted in an 18% increase in 
sensitivity of FCM detection of aneuploidy (10/38 samples 
with one-parameter DNA analysis versus 15/38 samples with 
two-parameter DNA and cytokeratin analysis). In addition, 
S-phase could be determined in the 15 aneuploid samples by 
means of the two-parameter analysis where this was not 
possible using only DNA content because of the overlap of 
diploid and aneuploid populations. FCM analysis allowed 
quantification of the percentage of tumor-cells expressing 
cytokeratin 18 which has previously been shown to correlate 
quantitatively with higher grade, higher stage TCC. The 
quantitative measurement of tumor-cell expression of 
cytokeratin 18 by FCM analysis appears to provide additional 
information of potential prognostic value, independent of 
tumor cell ploidy and proliferative fractions. 
INTRODUCTION 
Flow cytometry (FCM) has been used extensively as a 
means of characterizing the DNA content of tumors and 
assessing their proliferative fraction (Braylan et al., 
1983; Laerum and Farsund, 1981). The routine clinical use 
of FCM analysis of tumor-cell DNA content and distribution 
has provided an important new parameter for assessing 
patient prognosis and response to therapy (Herman and 
Vooijs, 1982; Herman et al., 1984). These data have also 
proved of value in urological tumors (Baisch et al., 1982; 
Devonec et al., 1982; Gustafson et al., 1982; Klein et al., 
1982a,b; Tribukait et al., 1982; Wijkstrom et al., 1984). A 
persistent problem in the interpretation of DNA data derived 
from FCM analysis of tumor specimens has been the variable 
admixture of non-tumor cells, primarily of stromal and 
inflammatory origin, with the tumor cells. The presence of 
these non-tumor cells has caused variable results in the 
interpretation of aneuploidy and proliferative fraction of 
solid tumor specimens (Herman and Vooijs, 1982). 
We have recently described a technique for analysing 
the DNA content of pure tumor-cell populations in spite of 
the presence of stromal and inflammatory cells in 
single-cell suspensions from tumors (Oud et al., 1985; 
Page 88 
Ramaekers et al., 1964a,b, 1985a). This technique exploits 
the fact that intermediate filament proteins are highly 
tissue-specific. Thus, carcinoma cells can be distinguished 
by their expression of cytokeratin proteins from stromal and 
inflammatory cells which do not contain cytokeratin 
proteins. 
Further application of immunopathologic techniques to 
transitional-cell carcinoma has demonstrated that expression 
of cytokeratin is altered by neoplastic changes in 
transitional epithelium (Ramaekers et al., 1985b). In 
particular, the 45 kD cytokeratin 18, generally found in 
glandular and other "simple" epithelia, is found in the 
superficial "umbrella" cells of normal transitional 
epithelium but not in the deeper cell layers. However, 
development of urothelial carcinomas is associated with an 
increased number of urothelial cells expressing this 
cytokeratin protein, as demonstrated by a highly specific 
monoclonal antibody (RGE53) (Ramaekers et al., 1985b). 
In the present study, we report the use of FCM to 
analyse the DNA content and distribution of 
transitional-cell carcinomas of the bladder, excluding 
analysis of admixed stromal and inflammatory cells by 
immunofluorescent labelling of carcinoma cells with 
antibodies to cytokeratin. In addition, further FCM 
analysis made possible the quantitative measurement of the 
45 kD cytokeratin 18 expression by bladder carcinoma cells. 
These two measurements considerably extend the reliability 
and information content of FCM analysis of bladder cancer. 
MATERIAL AND METHODS 
Thirty-eight transurethral resection specimens of 
bladder carcinomas were used as well as a lymph node 
metastasis. The material was divided into 3 parts: one 
part was fixed in formalin and embedded in paraffin for 
routine histology, one was snap frozen in liquid nitrogen 
for immunohistochemical staining, and the third was used for 
preparation of a single-cell suspension for FCM. 
Routine histological classification was done from H. 
and E.-stained paraffin sections according to the WHO 
grading system (WHO, 1973). Clinical staging was performed 
in accordance with the rules of the International Union 
Against Cancer (Harmer, 1982). 
A single-cell suspension of the fresh tissue was 
prepared as described before (Herman et al., 1983). In 
brief, the tissue was minced with scissors in a sterile 
centrifuge tube and incubated with a mixture of collagenase 
Type II (1176 U/ml, Worthington, Freehold, NY) and DNase I 
(200 U/ml, Sigma, St. Louis, MO) at 37C for 2 h. After 
enzymatic incubation, McCoy's wash (Gibco, Paisley, U.K.) 
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was added and the cell suspension was passed through a 300-u 
metal sieve, a 25-gauge needle and a gas-sterilized 100-u 
pore size nylon filter (Ortho Diagnostic Systems, Beerse, 
Belgium). The cells were centrifugea at room temperature at 
400 g for 5 min, after which the supernatant was discarded 
but fluid sticking to the wall of the tubes was allowed to 
cover the pellet. The pellet was vortexed vigorously and 
the cells were resuspended in the small volume of McCoy's 
wash. Then 70% ethanol (-20 С) was added rapidly under 
constant vortexing or shaking. The final cell concentration 
was about 3 χ Юеб cells/ml ethanol. At this stage the 
cells could be stored at -20 С for several days. 
Immunohistochemical staining procedures and antibodies 
Frozen sections of normal human bladder tissues, 
primary TCC's and tumors, as well as a TCC lymph-node 
metastasis, were incubated with antibodies to cytokeratins 
by the indirect immunofluorescence technique (Ramaekers et 
al., 1983b). Antibodies used in this study were: (1) An 
affinity-purified polyclonal rabbit antiserum to human skin 
keratins (pKer) which reacts with virtually all epithelial 
tissues, but not with non-epithelial tissues. The antiserum 
was diluted 1:5 in PBS for staining of cells in suspension 
and 1:25 for staining of frozen sections. (2) RGE53, a 
monoclonal antibody to cytokeratin 18, one of the 19 
cytokeratins present in human epithelial tissues (Debus et 
al., 1982; Moll et al., 1982). This antibody is specific 
for glandular epithelia and does not react with squamous 
epithelia (Ramaekers et al., 1983a). Undiluted culturing 
supernatant was used for labelling of cell suspensions and 
frozen sections. Ethanol fixed cell suspensions from the 
bladder carcinomas were split into 4 fractions. One sample 
was stained with propidium iodide (PI) as described below 
and used for DNA measurements. A second sample was used for 
the calculation of the DNA-index, using chicken red blood 
cells (CRBC) as internal standard (Hamilton et al., 1980; 
Tannenbaum et al., 1978). 
The third and fourth samples were stained separately 
with the antibodies pKer and RGE53 as follows. About 1 χ 
Юеб cells in ethanol (70%,-20 С) were centrifugea at room 
temperature (1.5 min, 400 g) and the pellet was resuspended 
with 1 ml of 5% fetal calf serum (FCS; Gibco) in buffer A 
(8.01 g NaCl, 0.2 g KCl, 1.44 g Na2HP04/ 0.2 g KH2P04 per 
1000 ml water, pH=7.4) and pelleted again. The pellet was 
resuspended in 0.2 ml of antiserum, either as culture 
supernatant (RGE53) or diluted in 5% FCS in Buffer A (pKer), 
and incubated for 30 min at room temperature with regular 
shaking. Then the cells were washed 3 times in 1.0 ml 
Buffer A containing 5% FCS. After the last washing step the 
cell pellet was resuspended in 0.5 ml of FITC conjugated 
second antibody, diluted 1:25 in Buffer A containing 5% FCS. 
As second antibody, either FlTC-conjugated goat-anti-rabbit 
IgG or FITC-conjugated rabbit-anti-mouse IgG (Nordic, 
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Tilburg, The Netherlands) were used. After incubation for 
30 min at room temperature with regular shaking the cells 
were washed as described above. The cell pellet was then 
resuspended in 1 ml of a PI solution (20 mg/1 A-grade in 150 
mM sodium phosphate buffer, pH 7.4; Calbiochem- Boehringer, 
La Jolla, CA). To 1 ml of this cell suspension, 0.1 ml of a 
stock solution of RNase (1% type A in sodium phosphate 
buffer; Sigma) was added and the suspension was incubated 
for exactly 10 min at 37 C. Then the cell suspension was 
filtered through a 100-u nylon filter (Ortho). Cells were 
kept in the dark at room temperature prior to FCM analysis. 
FCM analysis 
Cell analysis and sorting were performed using a 
Cytofluorograph 50H (Ortho Instruments, Westwood, MA). 
Fluorchromes PI and FITC were excited at 488 nm with an 
argon ion laser (Spectra Physics, Mountain View, CA). 
Fluorescence was measured simultaneously using a 515-530-nm 
bandpass filter and a 630-nm longpass filter for FITC and 
PI, respectively. A correction was made for leakage of FITC 
fluorescence into the PI channel. All data were stored in 
correlated (list) mode on a PDP 11/34 computer (Digital 
Equipment Corporation, Marlboro, MA) for subsequent data 
analysis. The normal human GÌ DNA-index in our laboratory 
is 2.65 to 2.75 times the fluorescence intensity of CRBC 
(Hiddeman et al., 1984). Samples with a DNA index of the 
second peak of more than 1.110 (mean normal Gl = 0.990 with 
a sd - 0.040) were classified as aneuploid. Cell cycle 
analysis was done for characterization of the Gl, S and G2M 
phases (Baisch et al., 1975). 
RESULTS 
Immunohistochemistry 
Frozen sections of normal bladder, primary TCC and a 
TCC lymph-node metastasis were incubated with the polyclonal 
and monoclonal antibodies pKer and RGE53. In normal bladder 
tissue, all epithelial cells are stained with the polyclonal 
cytokeratin antibody pKer, while only the superficial layer 
of transitional epithelium is stained with the antibody to 
cytokeratin 18 (RGE53) (Fig.la,b). In low-grade, low-stage 
tumors a comparable staining pattern is seen (Fig.lc,d), 
while in the high-grade, high-stage tumors most epithelial 
tumor cells express cytokeratin 18 (Fig.le,f). In a 
lymph-node metastasis all epithelial cells expressed 
cytokeratin 18 (Fig.lg,h). 
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Figure 1 Immunofluorescence micrographs of normal human 
bladder epithelium (a,b), a low-grade, low-stage TCC (c,d), 
a high-grade, high-stage TCC (e,f) and a lymph-node 
metastasis of a TCC (g,h) stained with the polyclonal 
anticytokeratin antiserum pKer (a,c,e,g) or with the 
monoclonal anticytokeratin 18 antibody RGE53 (b,d,f,h). 
Note the increase in the relative number of RGE53-positive 
cells as a function of neoplastic progression. Bar 
indicates 50 um. 
Page 92 
Labelling of tumor cells in single-cell suspensions and 
FCM analysis 
When ethanol fixed cell suspensions from 38 bladder TCC 
were incubated with the polyclonal cytokeratin antibody 
(pKer) and thereafter with an appropriate FITC-conjugated 
second antibody and PI, the epithelial tumor cells could be 
distinguished from stromal and inflammatory cells. Analysis 
of the cytokeratin and Pi-positive bladder cells revealed 
tumor cells ranging in DNA-index from 0.94 to 3.58 (normal 
human diploid equals 1.0). An example of such a 
two-parameter FCM analysis is shown in Figure 2. In the 
one-parameter analysis an abnormal DNA stemline is shown in 
this case of TCC (Fig.2a). Two-parameter analysis for PI 
and pKer in a two-dimensional projection (Fig.2b), allows 
the stromal and inflammatory cells (Fig.2c) to be clearly 
distinguished from the cytokeratin-positive aneuploid tumor 
cells (Fig.2d) and also from cytokeratin-positive but 
diploid normal bladder epithelial cells, although a 
percentage of the aneuploid cell fraction is negative for 
pKer. This aneuploid fraction negative for cytokeratin is 
represented by naked nuclei from TCC tumor tissue, as judged 
from microscopic inspection of sorted fractions from the 
cell suspension. The proliferative fraction ( S- and G2M 
phase) of the tumor can now be estimated after labelling 
with pKer. 
Detection of small numbers of tumor cells and estimation of 
their ploidy 
In the case of some tumor-cell suspensions, containing 
only small numbers of aneuploid cells, it was not possible 
to detect the tumor cells using the one-parameter DNA 
analysis of the sample stained only with PI (Fig.3a). 
However, after application of the two-parameter technique, 
we could detect aneuploidy in 15/38 samples instead of the 
10/38 samples detected by using one-parameter DNA analysis 
(Fig.3b). This represents an increase of 17,9% in the 
detection of aneuploidy (5/28 samples considered diploid by 
single parameter analysis) with a confidence value of 
6.06-36.89% at 95% and 4.07-42.8% at 99%. 
The two-parameter labelling technique also increased the 
evaluability of samples containing large amounts of debris, 
usually a result of surgical and/or preparative procedures. 
Again epithelial cells can be detected and analysed 
separately. These cells can be sorted and identified as 
tumor cells in the microscope. 
Furthermore cytokeratin antibodies in FCM were used for the 
recognition of slightly aneuploid cells in the cell 
population. Such cell fractions were recognized as a 
shoulder in the first Gl-peak in some specimens (Fig.3c). 
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Figure 2 Example of two-parameter FCM analysis of a 
high-grade, aneuploid TCC using the polyclonal cytokeratin 
antibody pKer in addition to DNA-staining with PI. (a) 
One-dimensional FCM DNA pattern of the cell suspension 
stained only with PI, containing CRBC as internal standard 
(first peak). Note the presence of both a diploid (channel 
40) and an aneuploid (channel 70) cell fraction. (b) A 
two-dimensional projection of DNA content (as PI 
fluorescence) and cytokeratin content (as FITC fluorescence) 
from the same cell suspension as in (a). Note both 
cytokeratin-positive, aneuploid cells (box) and 
cytokeratin-negative, diploid cells. An aneuploid fraction 
of naked nuclei (cytokeratin-negative) is also observed. 
(e) DNA histogram of the cytokeratin-negative cells from 
(b), analysed separately by placing a square window around 
the cytokeratin-positive cells. (d) DNA histogram and 
cell-cycle parameters of the cytokeratin-positive cells, 
present within the window in (b). 
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By means of the two-parameter technique and a 
two-dimensional projection of the DNA content (PI) and the 
cytokeratin content (pKer), it was possible to select the 
epithelial cells (Fig.3d) from the non-epithelial cells and 
analyse these fractions separately for their DNA content and 
proliferative fraction. 
Cell-cycle analysis 
In those samples (20/38) which did not contain 
excessive debris or cell clumps, we could estimate the 
number of cells in the S-phase. The percentage of cells in 
S-phase could be correlated with the histological grade of 
the tumors (Fig.4a). We found a significant increase in the 
percentage of cells in S-phase with increasing histologic 
grade of the tumor. It should also be noted that almost all 
of the grade-III tumors are aneuploid, while the 2 aneuploid 
grade-II tumors show an S-phase fraction higher than the 
mean value estimated for all grade-II TCC's. 
Expression of cytokeratin 18 by tumor cells 
We have reported above (see also Ramaekers et al., 
1985b) that when frozen sections of TCC are stained with 
RGE53, tumors of higher grade and higher stage contained 
increased numbers of cells expressing cytokeratin 18, as 
shown by an RGE53-positive staining pattern. In the 
analysis of low-grade, low-stage TCC with both polyclonal 
(pKer) and monoclonal (RGE53) antibodies in combination with 
PI, variable numbers of cells showed a positive staining 
reaction with the polyclonal cytokeratin antibody. Only a 
low percentage of these tumor cells expressed cytokeratin 18 
(as detected by RGE53) in these low-grade tumors. In 
contrast, high-grade, high-stage tumors showed quite a 
different staining pattern. In all samples, again variable 
numbers of cells were positive for the polyclonal 
cytokeratin antibody. Within these high-grade tumors a 
higher percentage of the tumor cells also expressed 
cytokeratin 18. In a lymph-node metastasis of a TCC all 
tumor cells were aneuploid while there was a complete 
overlap in the fractions staining with the polyclonal and 
monoclonal antibodies to cytokeratin. As a control, a 
sample with RAM-FITC was analysed and all cells were 
negative with this control staining. A correlation between 
the percentage of cells expressing cytokeratin 18 (as 
related to the total of epithelial pKer-positive cells) with 
the histological tumor grade is shown in Figure 4b. An 
increase in cells expressing cytokeratin 18 is seen with 
increasing tumor grade, independent of S-phase or ploidy of 
the tumor cells. 
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Figure 4 (a) Correlation between the percentage of 
суtokeratin-positive tumor cells in S-phase and histologic 
grade of TCC tumors. Mean GI:3.4 (sd = 1.Θ3), GII:7.51 (sd 
» 2.98), GIII:15.04 (sd - 8.72) (Wilcoxon test for degree of 
significance: Gl-G2:p-0.022, Gl-G3:p-0.014, G2-G3:p-0.014). 
The horizontal bars indicate the mean values, (b) Histogram 
showing the relation between tumor grade, ploidy and 
percentage of cells positive for RGE53 (cytokeratin 18) as 
related to the total number of epithelial tumor cells, 
estimated by labelling with pKer (compare figure 1). Mean 
GI:0.02 (sd - 0.014), GII:0.165 (sd - 0.115), GIII:0.442 (sd 
• 0.353) (Wilcoxon test for the degree of significance: 
Gl-G2:p=0.029, Gl-G3:p-0.018, G2-G3:p=0.107). χ - diploid 
sample, о - aneuploid sample. Horizontal bars indicate the 
mean values. 
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DISCUSSION 
Flow cytometric analysis of TCC offers new diagnostic 
tools for the clinician and provides new prognostic values 
(Lovett et al., 1984; Herman et al., 1984). The use of 
tissue-specific markers in combination with DNA analysis in 
flow cytometry may give more reliable analysis of epithelial 
tumors. When polyclonal and monoclonal antibodies to 
cytokeratins are used, normal epithelial cells and carcinoma 
cells can be labelled specifically by the indirect 
immunofluorescence technique. Non-epithelial cells, stromal 
cells, blood cells and inflammatory cells do not stain with 
cytokeratin antibodies. Therefore, these antibodies are 
already widely used as tissue markers for histopathology and 
cytopathology (Ramaekers et al., 1983b). Flow cytometric 
analysis of mixed cell populations, such as are obtained 
from tumors, produces results which are often difficult to 
interpret because of the admixture of cells of interest, 
usually carcinoma cells, with other cells such as 
inflammatory and stromal cells. In some cases these cell 
populations can be easily distinguished but most tumor 
material is still difficult to analyse and to interpret by 
FCM (Herman et al., 1984). Because of the ubiquitous 
presence of cell-type-specific intermediate filaments, 
immunofluorescence of these structures using specific 
antibodies can be used for FCM analysis of many solid tumors 
(Ramaekers et al., 1984a,b, 1985b). All carcinomas can be 
distinguished from non-epithelial cells by broad-spectrum 
cytokeratin antibodies and specific epithelial cell types 
can be further recognized by means of monoclonal antibodies 
against particulier subclasses of cytokeratin. 
Three advantages of the application of cytokeratin 
antibodies in FCM analyis have become obvious from the 
present experiments. First, in those cases of carcinoma 
having only a very small fraction of cells with an abnormal 
stemline, these cells can be detected by the two-parameter 
analysis. Even in samples containing a large amount of 
debris, which are not évaluable by one-parameter FCM 
analysis, cells with an abnormal DNA content can be detected 
by two-parameter FCM analysis. When the epithelial fraction 
is not clearly visible as a peak in the one-parameter DNA 
histogram, its exact position can still be determined by 
recognition of the epithelial cells through the 
epithelium-specific cytokeratin markers. This offers the 
opportunity to detect abnormal, aneuploid stemline cells in 
more tumors than is possible with one-parameter FCM 
analysis. Second, the two-parameter analysis offers the 
posibility to study the cell fraction of interest, in our 
case the carcinoma cells, and to analyse the cell cycle of 
the tumor. In the analysis of TCC's we have found a 
significant increase of cells in S-phase in correlation with 
increased grade of the tumor cells. These values of the 
S-phase fractions of TCC's are theoretically more reliable 
then those published by Tribukait et al. (1982), since we 
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have only used S-phase values of the epithelial 
pKer-positive cell population and not the S + G2M fraction 
of the total cell population. It remains to be evaluated 
whether or not this refinement in FCM methods gives a better 
correlation with prognosis than the methods used so far. in 
all estimations one has to keep in mind that a certain 
percentage of the tumor cells lose their cytoplasm during 
preparation of the cell suspension and thus are 
cytokeratin-negative. This phenomenon, however, does not 
interfere with the calculation of the percentage of 
cytokeratin 18-positive tumor cells. Its influence on the 
estimation of the proliferative fraction of TCC's is under 
study. 
A third advantage of potential clinical value of the 
two-parameter analysis of tumors lies in the differential 
staining patterns of the tumor cells with different types of 
cytokeratin antibodies. An increase in cells expressing 
cytokeratin 18 was seen with an increase in malignancy in 
frozen sections of TCC's (Ramaekers et al., 1985b). This 
phenomenon has now been quantified following FCM analysis of 
these tumors. In low-grade, low-stage TCC only a small 
percentage of the tumor cells expres cytokeratin 18 (as 
detected by RGE53), while in a lymph-node metastasis all 
tumor cells express cytokeratin 18. In fact, this latter 
result further extends and confirms our earlier observations 
in primary TCC's (Ramaekers et al., 1985b). The correlation 
between the percentage of tumor cells expressing cytokeratin 
18 and an increase in malignancy, expressed as grade of the 
tumor, although not yet seen for each individual tumor, may 
offer the clinician a new prognostic criterion in the 
evaluation of TCC. 
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ABSTRACT 
Nine primary human renal-cell tumors (RCT), one 
lymph-node metastasis, 4 human xenografts of a RCT in nude 
mice and a rat RCT line were analysed by flow cytometry 
(FCM) using propidium iodide for DNA analysis and antibodies 
to cytokeratin and vimentin in the indirect 
immunofluorescence technique for labelling of specific 
tumor-cell populations. By means of 2-dimensional FCM 
analysis, vimentin- and cytokeratin-positive (tumor) cells 
were compared and their DNA content and proliferative 
fraction analysed separately from those of 
cytokeratin-negative stromal and inflammatory cells. In 
primary human RCT, 2 subpopulations of cells were detected 
and analysed separately. Small numbers of tumor cells with 
an abnormal DNA stemline were also detected. In addition, 
co-expression of intermediate filament proteins of both the 
cytokeratin and the vimentin types was detected in the 
aneuploid cell population. Comparison of 2 model systems of 
RCT with primary human RCT revealed a similar pattern of 
tumor-cell subfractions within these tumors. The 
2-parameter FCM analysis permits the detection of 
subpopulations in complex cell suspensions and the 
quantification of these fractions, as well as analysis of 
their cellular DNA content. 
INTRODUCTION 
In a recent report (Feitz et al., 1985) we have 
evaluated the usefulness of DNA flow cytometry (FCM) in 
combination with staining of the cytoplasmic intermediate 
filament proteins in bladder carcinomas. These 
tissue-specific proteins can be detected 
immunocytochemically by means of monoclonal and polyclonal 
antibodies and can be used in the FCM analysis of complex 
human tumors (Ramaekers et al., 1984a,b, 1986). In 
particular, antibodies to cytokeratins, the intermediate 
filament proteins specific for epithelial cells, enable 
carcinoma cells to be analysed separately from the 
non-epithelial stromal and inflammatory cell components that 
are present in most tumors. 
Investigation of human primary renal-cell tumors (RCT) 
showed that these neoplasms contain several tumor-cell 
populations, each with a different intermediate filament 
staining pattern. Cytokeratin was found in many tumors, but 
nearly all tumors co-expressed the mesenchymal type of 
intermediate filament protein vimentin. However, primary 
RCT and lymph node metastases of RCT also contained either 
cytokeratin or vimentin only (Herman et al., 1983a). 
Therefore, we suspect that biological differences in the 
subfractions of RCT may give rise to differences in 
behaviour of tumor metastases, and undoubtedly have 
consequences for chemotherapy. 
Page 106 
The development of model systems for further cell 
biological and experimental investigations of RCT has led to 
the establishment of 4 human renal-cell xenografts in nude 
mice (Kurth et al., 1984) and of a tumor line from a rat RCT 
in Wistar Lewis rats (deVere White et al., 1980). In this 
study, we present findings on the 2-parameter FCM analysis 
of cellular DNA and intermediate filament content of these 
RCT models in comparison with primary human kidney tumors. 
We have tried to answer the following questions: 
(1) Does application of this 2-parameter analysis to RCT 
allow separation of the tumor cells from inflammatory and 
stromal cells, making it possible to estimate ploidy and 
proliferative fractions more accurately, as in the case of 
bladder carcinoma (Feitz et al., 1985)? (2) Do aneuploid 
(tumor) cells contain both cytokeratin and vimentin? (3) 
How can RCT animal model systems be compared with primary 
human RCT? 
MATERIAL AND METHODS 
Nine primary renal-cell tumors (HCT) and one RCT 
metastasis (number 1 to 10 in Table I), 4 human RCT 
xenografts in nude mice (designated RC2, RC14, RC43, NC65) 
and a rat RCT line (designated rRCT) continuously 
retransplanted in Wistar Lewis rats (deVere White et al., 
1980) were used in this study (Table I). Representative 
parts of tumor tissue were chosen which included all 
macroscopically identifiable histological patterns of the 
tumor. Necrotic and hemorrhagic areas were excluded. The 
material was divided into 3 parts: one part was fixed in 
formalin and embedded in paraffin for routine histology, 
another was snap frozen in liquid nitrogen for 
immunohistochemical staining reactions, and a third was used 
for preparation of a single-cell suspension for FCM. 
Routine histological classification was done from 
hematoxylin-eosine-stained paraffin sections (Bennington and 
Beckwith, 1975). 
Cell suspensions were prepared from the fresh tissues 
as described before (Herman et al., 1983b; Feitz et al., 
1985). From solid tumor material single-cell suspensions 
were prepared by mechanical and enzymatic disaggregation 
using a mixture of collagenase Type II (1176 U/ml, 
Worthington, Freehold, NY) and DNase I (200 U/ml, Sigma, St. 
Louis, MO) at 37C for 2 h. After 3 subsequent filtration 
steps (300-u metal sieve, 25-gauge needle and 50-70 u pore 
size nylon filter) a single-cell suspension was obtained and 
the cells were fixed in 70% ethanol (-20C) and stored at 
-20C to -40C until further processing. 
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Table I 
DNA index of RCT obtained after the one- (DNA INDEX) and 
2-parameter FCM analysis. (DNA INDEX pKer and DNA INDEX 
pVim). In the cases in which an aneuploid tumor cell fraction 
was present, the DNA index of this latter fraction is given 
only 
NUMBER 
1 
2 
3 
4 
5 
6 
7* 
θ 
9 
10 
RC2 
RC14 
RC4 3 
NC65 
rRCT 
DNA INDEX 
0.97 
0.80/2 
1.40 
0.98 
0.94 
0.96 
0.95 
1.19 
0.93 
1.66 
1.40 
1.87 
2.24 
0.97 
0.98 
DNA INDEX (pKer) 
0.97 
0.80/2 
1.36 
1.30/1 
0.94 
1.60/1 
1.54/1 
1.30 
0.96 
1.66 
1.39 
1.84 
2.29 
1.88/1 
1.88/1 
DNA INDEX (pVim) 
0.97 
1.05/2 
1.35 
1.35/1 
0.94 
1.60/1 
- /3 
1.17 
0.97 
1.66 
1.40 
1.77 
2.35 
1.92/1 
1.87/1 
(1) In these cases labelling with either cytokeratin or 
vimentin antibodies resulted in the detection of an aneuploid 
peak not seen without labelling. 
(2) Hypoploid tumor cell fraction present in the suspension 
(cf. Fig. 2c,d). 
(3) Some aneuploid cells. 
Human RCT (1 to 10, 7* is a lymph-node metastasis from 6), RCT 
xenografts (RC2, RC14, RC43, NC65) and a rat RCT (rRCT). 
Immunohistochemical staining procedures and antibodies 
Frozen sections of normal kidney tissue, primary RCT 
and a metastasis, as well as 4 xenografts of RCT and a rat 
RCT, were incubated with intermediate filament antibodies by 
the indirect immunofluorescence technique (Ramaekers et al., 
1983b). Antibodies used in this study were: (1) An 
affinity-purified polyclonal rabbit antiserum to human skin 
keratins (pKer) which reacts with virtually all epithelial 
tissues, but not with non-epithelial tissues. The antiserum 
was diluted 1:5 in PBS for staining of cells in suspension 
and 1:25 for staining of frozen sections. (2) An antiserum 
to calf lens vimentin (pVim), raised in a rabbit. 
Preparation and specificity of this antiserum have been 
described (Ramaekers et al., 1983b). 
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Ethanol-fixed cell suspensions from RCT were split into 4 
fractions. One sample was stained with propidium iodide 
(PI) as described below and used for cell kinetic studies. 
A second sample was used for calculation of the DNA index, 
using chicken red blood cells (CRBC) as internal standard 
(Hamilton et al., 1980; Tannenbaum et al.,1978). The other 
2 samples were stained separately with the antibodies pKer 
and pVim (Feitz et al., 1985; Oud et al., 1985; Ramaekers et 
al., 1984a,b, 1986). In brief, cells were incubated for 30 
min with the antibody directed against the specific 
intermediate filament proteins, washed several times, and 
incubated with an appropriate FITC-conjugated second 
antibody for 30 min. Thereafter, DNA staining was performed 
using propidium iodide (PI) on RNase treated cells. 
FCM analysis 
Cell analyses were performed using a 
Cytofluorograph 50H (Ortho Instruments, Westwood, MA) as 
described before (Feitz et al., 1985). All data were stored 
in correlated (list) mode on a PDP 11/34 computer (Digital, 
Marlboro, MA) for subsequent data analysis. The normal 
human GÌ DNA-index in our laboratory is 2.65 to 2.75 times 
the fluorescence intensity of CRBC (Hiddeman et al., 1984). 
Cell cycle analysis was done as described by Baisch et 
al.(1975). As a control, cells incubated only with a 
FITC-conjugated second antibody were analysed and in this 
control all cells were negative. 
RESULTS 
Immunohistochemistry 
Frozen sections of normal kidney, primary RCT and a 
metastasis, human xenografts of RCT in nude mice and a rat 
RCT were incubated with the antibodies pKer and pVim 
(Fig.l). In normal kidney tissue, epithelial structures 
such as collecting ducts and parietal glomerular epithelial 
cells are stained with the cytokeratin antibody. Staining 
with the vimentin antibody is found only in endothelial and 
peritubular cells, in vascular walls and glomerular cells 
(Fig.la,b). Primary human RCT and xenografts of these 
tumors as well as a rat RCT were found to react with both 
the cytokeratin and the vimentin antibodies (Fig.lc-h). In 
double-labelling studies it was seen that vimentin-positive 
cells were also positive for cytokeratin (see also Herman et 
al., 1983a). 
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Figure 1 Immunofluorescence microgaphs of normal kidney 
(a,b), a primary human renal-cell tumor (ed), a xenograft 
of a human renal-cell tumor in a nude mouse (NC65) (e,f), 
and a rat renal-cell tumor in Wistar Lewis rats (rRCT) 
(g,h), stained with the cytokeratin antiserum pKer (a,c,e,g) 
or with the vimentin antiserum pvim (b,d,f,h). Note the 
co-expression of both types of intermediate filament 
proteins in tumor cells, a-h, X150. 
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Figure 2 Example of a 2-parameter FCM analysis of a primary 
human RCT (No.3) (a, b) containing an aneuploid tumor-cell 
population positive for cytokeratin (a, c) and vimentin (b, 
d) in addition to a diploid peak containing stromal and 
inflammatory cells (A = aneuploid, D = diploid DNA index). 
Note that in the tumor-cell suspension containing a 
hypoploid fraction (No.2) (c, d) no tumor cells positive for 
vimentin are seen (d). 
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Labelling of RCT in single-cell suspensions and FCM analysis 
Ethanol fixed tumor cells in a single-cell suspension 
were incubated with the antibodies pKer and pVim and 
thereafter with the FITC-conjugated second antibody and PI. 
in the 9 primary human RCT and the lymph-node metastasis, 
analysed in this way, the vimentin-positive cell population 
contains stromal cells and inflammatory cells (Fig.2d) next 
to the tumor cells, which become clearly visible as an 
aneuploid peak in 7/10 cases (see Table I and Fig.2b). In 
these cases nearly all tumor cells are also 
cytokeratin-positive (Fig.2a,c). The cytokeratin-negative 
cell population is represented by the stromal and 
inflammatory cells of mesenchymal origin which are 
vimentin-positive. Table I summarizes the FCM data obtained 
for these human RCT before and after immunolabelling. This 
immunolabelling procedure made it possible to detect an 
abnormal DNA stemline in RCT in 7/10 instead of 4/10 
samples. 
An example of analysis of a tumor-cell suspension from 
a RCT xenograft in nude mice is shown in Figure 3. Figure 
3a shows the normal DNA histogram before labelling with 
intermediate filament antibodies. After labelling with the 
cytokeratin antibodies, epithelial (tumor) cells can be 
identified and their DNA content and cell cycle parameters 
analysed (Fig.3b,d). As expected from our 
immunohistochemical findings, tumor cells with an abnormal 
DNA stemline are also found in the vimentin-positive 
fraction (Fig.3c). These can also be analysed for their DNA 
content and proliferative fraction by placing a window 
around the vimentin-positive cells. Both the cytokeratin-
and vimentin-positive cell fractions show a similar or 
identical DNA index, indicating co-expression of both 
intermediate filament proteins in a certain number of the 
tumor cells. Similar data have been obtained for the rat 
RCT model system. 
Figure 4 Comparison of the 2-parameter FCM analysis of a 
primary human renal cell tumor (No.4) (a, b) with 2 tumor 
model systems, one xenograft of a human RCT in a nude mouse 
(NC65) (c, d) and a rat RCT (rRCT) (e, f). (a, b) 
Two-dimensional projections of the DNA content and the 
cytokeratin-positive (a) and vimentin-positive (b) cell 
fractions of a primary human renal-cell tumor. (c,d) 
Projections of DNA content and cytokeratin (c) and vimentin 
(d) content of a xenograft of the human renal-cell tumor, 
and (e,f) a rat renal-cell tumor (cytokeratin in e and 
vimentin in f). Note that in all cases the tumor fraction 
is cytokeratin- and vimentin-positive next to 
vimentin-positive stromal cells (A » aneuploid, D = diploid 
DNA index). 
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Figure 4 compares 2-parameter DNA analysis of a primary 
human RCT (Fig.4a,b) with that of a human RCT xenograft in a 
nude mouse (Fig.4c,d) and that of the rat RCT (Fig.4e,f). 
All 4 cases of human RCT xenografts in nude mice contained 
an abnormal DNA stemline. Tumor cells expressing 
cytokeratins were found in all 4 tumors while a positive 
staining reaction was also found with the vimentin 
antibodies in the tumor-cell population (Fig.4d), although 
with varying intensity. The DNA content of tumor cells in 
the xenografts, however, is higher than that of the primary 
human RCT (see Table I and compare Fig.4a,b with Fig.4c,d). 
The rat RCT, analysed with the 2-parameter FCM analysis, 
also contained an abnormal DNA stemline with a DNA index of 
1.Θ8. The tumor fraction contained aneuploid cells 
expressing both cytokeratin (Fig.4e) and vimentin (Fig.4f). 
DISCUSSION 
Flow cytometric analysis of renal-cell tumors offers a 
new diagnostic tool for the clinician and has additional 
prognostic value (Baisch et al., 1982; Herman et al., 1984). 
Tumors can be further subclassified on the basis of this 
technique and selection of patients at risk is made possible 
by detection of biologically important cell fractions 
(Ljungberg et al., 1985; Lovett et al., 1984; Otto et al., 
1984; Schwabe et al., 1983; Verheyen et al., 1985). The use 
of tissue-specific markers, such as cytokeratins, in 
combination with DNA analysis in flow cytometry permits 
better analysis of tumor fractions within cell suspensions 
and may provide further information about subfractions in 
complex tumors (Feitz et al., 1985). When polyclonal and 
monoclonal antibodies to cytokeratin and vimentin are used, 
cell subpopulations can be separately analysed by the 
indirect immunofluorescence technique. These antibodies are 
already widely used as tissue-specific markers in 
inununohistopathology and cytopathology (Ramaekers et al., 
1983b). The use of these tissue-specific markers in flow 
cytometric analysis of complex tumors has been described for 
some tumor types (Feitz et al., 1985; Oud et al., 1985; 
Ramaekers et al., 1986). In this study the advantages of 
application of the cytokeratin and vimentin antibodies in 
2-parameter FCM analysis of renal-cell tumors have been 
demonstrated. First, by means of 2-parameter FCN analysis 
the cytokeratin-positive tumor-cell population can be 
separated and the DNA content of the tumor cells calculated 
more precisly than without labelling. Malignant cells from 
RCT can be analysed for their DNA content, separately from 
stromal and inflammatory cells, with antibodies to 
cytokeratin for specific labelling. As in the case of 
bladder carcinomas (Feitz et al., 1985), in RCT-cell 
suspensions containing only a low percentage of tumor cells, 
the 2-parameter FCM method makes it possible to detect this 
malignant fraction and to determine its ploidy and 
proliferative capacity. The detection of tumor cells with 
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an abnormal DNA stemline therefore becomes more sensitive. 
Second, in several cases of RCT in which an abnormal DNA 
stemline was present, a positive staining pattern of the 
tumor cells with both cytokeratin and vimentin was seen. 
Co-expression of these proteins in RCT cells is to be 
expected. The FCM data presented here thus confirm our 
earlier immunohistochemical findings (Herman et al., 1983a). 
They clearly show that aneuploid cells (the tumor cells) of 
RCT contain both cytokeratin and vimentin. Thirdly, 
quantification of the different biological subfractions in 
RCT becomes available. It remains to be evaluated whether 
or not this refinement in the classification and 
quantification of subpopulations gives more information and 
better correlation with the prognosis of the patients. 
In a comparison of 2 RCT model systems with some of the 
human RCT obtained from patients, comparable biological 
properties of tumor cells were found. First, in all 
xenografts as well as in the rat tumor model an abnormal DNA 
stemline was found. This tumor fraction could be analysed 
separately from animal stromal cell components and 
quantified by the 2-parameter FCM analysis. The 
intermediate filament staining pattern found in these model 
tumors is therefore comparable to the pattern found in most 
primary human RCT. Co-expression of cytokeratin and 
vimentin was seen in these tumors, since aneuploid cells 
were found in both fractions and all cells which were 
cytokeratin- and vimentin-positive had about the same DNA 
index. 
Therefore, the use of a combination of 
immunohistochemical and flow cytometric techniques in the 
investigation of complex tumors may provide additional 
information about subpopulation characteristics and 
biological potentials, independent of histological 
parameters. Whether this information can be translated into 
more effective prognostic criteria and patient management 
remains to be demonstrated. 
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SUMMARY AND CONCLUSIONS 
The development and use of highly specific antibodies 
to intermediate filament proteins has provided surgical 
pathology with 'a valuable tool for diagnosis (14, 1Θ). In 
this thesis the use of monoclonal and polyclonal antibodies 
to intermediate filament proteins in urological tissues and 
tumors and their application in the flow cytometric analysis 
of such tumors has been evaluated. 
In normal kidney tissue an immunohistochemical 
differentiation between mesenchymal and epithelial cells is 
possible, the mesenchymal cells being positive for vimentin 
and the epithelial cells for cytokeratin. In the epithelial 
cell component, subpopulations can be distinguished based on 
the presence of different cytokeratin subunits. In kidney 
tumors, especially renal cell carcinomas and nephroblastomas 
two different types of intermediate filament proteins are 
expressed simultaneously in part of the tumor cells. 
Furthermore it could be shown that renal cell carcinomas and 
nephroblastomas express different cytokeratins. This 
suggests that these two types of kidney tumors arise from 
different parts of the kidney epithelium. The results 
suggest that the adult renal cell carcinoma is derived from 
the proximal tubular epithelium, while the childhood 
nephroblastomas contain a cytokeratin (nr. 7) which in the 
kidney occurs only in the larger collecting ducts and the 
parietal epithelium. Future studies will have to show 
whether or not the different fractions of these tumors show 
a different metastatic behaviour and response to different 
treatment protocols. 
In urinary bladder epithelium expression of cytokeratin 
IB epitopes seems to change with differentiation or 
malignant progression. In the epithelial cell layers of 
normal bladder epithelium cytokeratin 18 is detected only in 
the superfical umbrella cells of the bladder, at least with 
some of the monoclonal antibodies directed against this 
specific subtype of cytokeratin (19, 21). Also in bladder 
transitional cell carcinomas, epithelial cells can be 
recognized with the help of the cytokeratin antibodies. The 
expression of certain cytokeratin 18 epitopes in 
transitional cell carcinomas changes in correlation with an 
increase of malignancy of the tumors (4, 5, 9, 13, 21). 
In prostate epithelial tissue two different cell types 
can be distinguished with the help of antibodies to 
different cytokeratin subtypes. These antibodies can also 
be used in the characterisation of prostate tumors. In 
highly differentiated prostate carcinomas the two different 
cell types can still be distinguished while poorly 
differentiated prostate carcinomas seem to be composed of 
one epithelial cell type. 
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From the cytokeratin pattern of these latter neoplasms it 
was concluded that they originate from the columnar 
epithelial cells (see also 2 and 3). 
In testis tissue only the epithelial cells lining the 
ducti efferentes and the rete testis are positive with 
cytokeratin antibodies. The seminiferous epithelium, 
however, contains only vimentin. In testis tumors the 
intermediate filament protein antibodies can distinguish 
between seminomatous and non-seninomatous tumors, which is 
especially important in cases of anaplastic tumors. 
Vimentin positive tumor cells are present in all seminomas, 
whereas these cells do not stain with cytokeratin 
antibodies. Occasionally, however, such tumors contain some 
cytokeratin positive cells. Non-seminomatous tumor cells 
react with the cytokeratin antibodies. In these tumors only 
the stromal components are positive for vimentin (1, 12, 
22). These immunohistochemical staining patterns provide an 
additional method to differentiate seminomatous from 
non-seminomatous testis tumors in surgical pathology. 
In order to further investigate the biological 
characteristics of urological tumors, flow cytometric 
studies were performed to estimate the DNA content and 
proliferative capacity of bladder tumors and renal cell 
tumors. In order to improve the DNA analysis of cell 
suspensions from solid tumors different intermediate 
filament protein antibodies were applied for the 
identification of specific cell populations present in such 
cell mixtures. In a model system of a mixture of an 
epithelial and a non-epithelial cell line it was possible to 
show that epithelial cells can be analysed separately from 
the non-epithelial cells after labelling for cytokeratin and 
DNA with PI. (17 and chapter IV). Also for cell 
suspensions from solid tumors this two-parameter flow 
cytometric analysis provides the opportunity to analyse 
epithelial cell populations separately from stromal and 
inflammatory cells. Therefore, this technique has been 
applied in several studies for the flow cytometric analysis 
of primary and metastatic human tumors (4, 5, 6, 16, 23). 
In the flow cytometric analysis of transitional cell 
carcinomas of the bladder with the use of cytokeratin 
antibodies it was possible to analyse epithelial- and 
non-epithelial cells separately. The detection of cell 
populations with abnormal DNA contents was increased with 
the help of the two-parameter flow cytometric analysis, 
especially in those cases were few tumor cells were present 
in the cell suspension. Furthermore, cell kinetic 
parameters could be studied in selected cell samples. With 
the help of a monoclonal cytokeratin 18 antibody an increase 
in the percentage of tumor cells positive with this antibody 
with increasing malignancy of the tumors was quantitated. 
This biological parameter of cellular characteristics may 
become an important factor in predicting the course of a 
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disease and give additional information for 
histopathological classification, (5, 21). 
in renal cell carcinomas the presence of a cell 
population with an abnormal DNA stemline seems to be of 
biological importance. Aneuploidy could be correlated with 
the clinical course of the patient and in vitro growth 
potential of such tumors (7, 15, 24). The different cell 
populations in human primary and metastatic renal cell 
tumors and renal cell tumor model systems, that can be 
recognized with the immunohistochemical staining techniques, 
can also be investigated separately for their DNA content 
using the two-parameter flow cytometric analysis. With this 
method, co-expression of vimentin and cytokeratin 
intermediate filament proteins was detected in renal tumor 
cells in the same (aneuploid) tumor cell population in most 
of the cases examined (6, Θ, 10, 11, 20). It could also be 
shown that the renal cell tumor model systems behave similar 
to the human tumors in this respect. 
It is concluded that the use of intermediate filament 
protein antibodies in the histopathological diagnostic 
procedures can be helpful in the further characterization 
and classification of tumors of the urogenital tract. 
Furthermore, these antibodies are strong tools in DNA flow 
cytometric investigations of different cell populations in 
solid tumors. These studies may therefore, in the future, 
provide additional information to the clinician in order to 
determine optimal treatment protocols and prognosis for 
individual patients. 
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De ontwikkeling en het gebruik van specifieke 
(monoclonale) antistoffen tegen intermediaire filament 
eiwitten zijn een waardevolle aanwinst in de pathologische 
(immuno) diagnostiek ter onderscheiding van de verschillende 
weefsels en tumortypen (14, 18). In dit proefschrift hebben 
we het gebruik van polyclonale en monoclonale antistoffen 
tegen intermediaire filamenteiwitten in urologische weefsels 
en tumoren, alsmede hun toepasbaarheid in de 
flowcytometrische analyse van deze tumoren, geëvalueerd. 
In normaal nierweefsel kan immunohistochemisch 
onderscheid gemaakt worden tussen epitheliale en stremale 
cellen, waarbij de mesenchymale cellen aankleuren met 
vimentine- en de epitheliale cellen met cytokeratine 
antilichamen. In de epitheliale celcomponenten kunnen 
subpopulaties onderscheiden worden op basis van hun 
verschillende cytokeratine patroon. In niertumoren, in het 
bijzonder niercarcinomen en nephroblastomen, komen 
verschillende typen intermediaire filamenteiwitten, namelijk 
vimentine en cytokeratine, tot expressie in een gedeelte van 
de tumorcellen. Verder kon aangetoond worden dat 
niercarcinomen en nephroblastomen een verschillend 
cytokeratinepatroon hebben. Dit suggereert dat deze twee 
typen niertumoren afkomstig zijn van verschillende delen van 
het nierepitheel. De resultaten suggereren dat niertumoren 
die voorkomen bij volwassenen afkomstig zijn van het 
proximale tubulus epitheel, terwijl nephroblastomen het 
cytokeratine (nr. 7) bevatten, dat in de nier alleen 
voorkomt in de grotere verzamelbuizen en het parietale 
epitheel. Toekomstig onderzoek zal moeten aantonen of 
verschillende tumorfracties een verschillend metastaserend 
gedrag en respons voor verschillende therapieprotocollen 
vertonen. 
In het overgangsepitheel van de blaas verandert de 
expressie van een cytokeratine 1Θ epitoop met differentiatie 
of maligne progressie. In de epitheliale cellaag van het 
normale blaasepitheel kan cytokeratine 18 alleen gevonden 
worden in de paraplucellen, althans met enkele van de 
monoclonale antistoffen gericht tegen dit specifieke 
cytokeratine subtype (19, 21). Ook in 
overgangscelcarcinomen van de blaas kunnen de epitheliale 
cellen herkend worden met behulp van de cytokeratine 
antistoffen. De expressie van bepaalde cytokeratine 18 
epitopen in overgangscelcarcinomen verandert in correlatie 
met een toename van de maligniteit van deze tumoren (4, 5, 
9, 13, 21). 
In epitheliaal prostaatweefsel kunnen twee 
verschillende celtypen onderscheiden worden met behulp van 
de antistoffen tegen de verschillende cytokeratine subtypen. 
Deze antistoffen kunnen ook gebruikt worden bij de 
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karakterisatie van prostaattumoren. In goed 
gedifferentieerde prostaatcarcinomen kunnen de twee 
verschillende celtypen nog onderscheiden worden, terwijl 
slecht gedifferentieerde prostaatcarcinomen samengesteld 
lijken te zijn uit ee'n epitheliaal celtype. Uit het 
cytokeratinepatroon van deze laatste maligniteit kon 
geconcludeerd worden dat het afkomstig is van het 
cylindrische prostaatepitheel (zie ook 2 en 3). 
In testisweefsel zijn alleen de epitheliale cellen die 
de ductuli efferentes bekleden en in de rete testis aanwezig 
zijn, positief met cytokeratine antistoffen. Het epitheel 
van de ductuli seminiferi bevat alleen vimentine. In 
testistumoren kan met behulp van de intermediaire 
filamentantistoffen een onderscheid gemaakt worden tussen 
Seminomen en de overige testis tumoren, wat vooral 
belangrijk is in het geval van anaplastische tumoren. 
Vimentine-positieve tumorcellen zijn aanwezig in alle 
Seminomen. Deze cellen worden over het algemeen niet 
gekleurd met cytokeratine antistoffen. Soms, echter, 
bevatten deze tumoren enkele cytokeratine-positieve cellen. 
Embryonaalcel-carcinomen en teratocarcinomen reageren met 
cytokeratine antistoffen. In deze tumoren zijn alleen de 
stromale componenten positief voor vimentine (1, 12, 22). 
Deze immunohistochemische kleuringsmethoden verschaffen een 
aanvullende methode voor de differentiatie van Seminomen en 
embryonaalcel-carcinomen en teratocarcinomen in de tumor 
diagnostiek. 
Om de biologische karakteristieken van urologische 
tumoren op een betere manier te kunnen onderzoeken, zijn 
flowcytometrische methoden gebruikt om het DNA-gehalte en de 
proliferatieve fractie van blaas- en niertumoren te bepalen. 
Om de DNA-analyse van celsuspensies van solide tumoren te 
verbeteren, hebben we gebruik gemaakt van de verschillende 
intermediaire filamenteiwit-antistoffen voor de 
identificatie van specifieke celpopulaties die aanwezig zijn 
in zulke celmengsels. In een modelsysteem van een mengsel 
van epitheliale- en niet-epitheliale cellen was het mogelijk 
om de epitheliale cellen van de niet-epitheliale cellen 
gescheiden te analyseren, na de labelling voor cytokeratines 
en propidium jodide (PI) (17 en hoofdstuk IV). Ook in 
celsuspensies van solide tumoren is het mogelijk om met 
behulp van de twee-parameter-flowcytoraetrische analyse 
methode epitheliale celpopulaties gescheiden van stromale en 
ontstekings cellen te analyseren. Daarom is deze techniek 
gebruikt in verschillende onderzoeken met als onderwerp de 
flowcytometrische analyse van primaire humane tumoren (4, 5, 
6, 16, 23). 
In de flowcytometrische analyse van 
overgangscelcarcinomen van de blaas was het mogelijk om 
epitheliale en niet-epitheliale cellen afzonderlijk te 
analyseren. De detectie van celpopulaties met abnormale 
DNA-gehaltes kon verbeterd worden met behulp van de 
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twee-parameter-flowcytometrische analyse, vooral in die 
gevallen waarbij maar weinig tumorcellen in de 
tumorcelsuspensies aanwezig waren. Verder konden 
celkinetische parameters bepaald worden in geselecteerde 
celmonsters. Met behulp van een monoclonale 
cytokeratine-18-antistof werd een toename van het percentage 
tumorcellen, positief voor deze antistof, met een toename 
van de maligniteit van de tumoren gevonden. Deze 
biologische parameter kan een belangrijke factor worden in 
de voorspelling van het verloop van de ziekte en aanvullende 
informatie geven voor de histopathologische klassificatie 
(5, 21). 
In niercarcinomen kan de aanwezigheid van een 
celpopulatie met een abnormaal DNA-gehalte van biologisch 
belang zijn. Aneuploidie is gecorreleerd met het klinische 
verloop van de ziekte en het in vitro groeipotentieel van 
deze tumoren (7, 15, 24). De verschillende celpopulaties in 
humane primaire en metastaserende niertumoren en 
niertumormodelsystemen, die kunnen worden herkend met behulp 
van de immunohistochemische kleuringstechnieken, kunnen ook 
afzonderlijk worden onderzocht op hun DNA-gehalte door 
middel van de twee-parameter-flowcytometrische analyse. 
Deze methode toonde een co-expressie van vimentine en 
cytokeratine intermediaire filamenteiwitten in 
niertumorcellen (6, 8, 10, 11, 20) in dezelfde (aneuploide) 
tumorcelpopulatie, in het merendeel van de onderzochte 
gevallen. Een gelijkwaardige bevinding werd gedaan in 
niertumormodel systemen. 
Uit het bovenstaande kan geconcludeerd worden dat het 
gebruik van intermediaire filamenteiwit-antistoffen in de 
histopathologische diagnostiek kan helpen bij de verdere 
karakterisering en klassificatie van tumoren van de tractus 
urogenitalis. Verder kan gesteld worden dat deze 
antistoffen bruikbaar zijn in DNA-flowcytometrische analyses 
van verschillende celpopulaties in solide tumoren. Deze 
onderzoeken zouden in de toekomst aanvullende informatie 
kunnen verschaffen om behandelings-protocollen en prognose 
voor iedere individuele patiënt te kunnen bepalen. 
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STELLINGEN 
Behorende bi] het proefschrift: Intermediate filaments as tissue 
specific markers in urological cancers 
1. Ook voor de expressie van intermediare-filamenteiwitten geldt de 
uitspraak: "tumors break rules". 
V. Gould, Arch. Pathol. Lab. Med., 1985, 109, 984-985. 
2. In analogie met het humane systeem zijn ook in het Dunning systeem 
de (anaplastische) epitheliale ratteprostaattumoren afkomstig van 
het cylinder epitheel en niet van het basale celcompartiment. 
Dit proefschrift en J. Isaacs en D. Coffey, in: Cancer of the 
prostate, G. Murphy (ed), W.B.Saunders Comp. Ltd, London, 1983. 
3. Bi] de strategiebepaling voor in vivo therapie van kanker m.b.v. 
monoclonale antιlichamen wordt nog te weinig rekening gehouden met 
de heterogene opbouw van bepaalde tumoren. 
4. Kwantitatief morfologisch onderzoek met lage resolutie heeft in 
tegenstelling tot kwantitatief morfologisch onderzoek met hoge 
resolutie slechts een diagnose bevestigende en geen diagnose 
stellende functie. 
5. De nieuwe kwantitatief morfologische methoden dienen op hun waarde 
getest te worden in klinische behandelings protocollen. 
6. De hedendaagse BCG-cystitis staat wat oorzaak en gevolg betreft in 
een schril contrast met het vroegere ziektebeeld. 
7. Een afnemende cicatnsatie gaat gepaard met een toenemende 
instrumentatie in de renale lithotherapie. 
8. Een groter aantal publicaties, zoals beoogd met het divergeren van 
onderzoek, betekent een gevaar voor de publicatie-index en de 
onderzoeksfinanciering. 
9. De besluiteloosheid ten aanzien van preventief onderzoek begint 
letterlijk en figuurlijk een maligne karakter te vertonen. 
10. Soms leiden niet de additionele experimenten maar een "whisky on 
the rocks" in een rocking chair tot de oplossing van een 
wetenschappelijk probleem. 
Nijmegen, 29 mei 1986, 
W.F.J. Feitz. 
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